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Abstract 
Abstract 
 
The Carnitine Palmitoyltransferase 1c (CPT1C) has recently been identified as a p53-
regulated brain-specific Carnitine Palmitoyltransferase (CPT) 1-family member. The CPT1-
family of proteins regulates fatty acid oxidation at the step of fatty acid import into the 
mitochondria. Three CPT1 genes, demonstrating generalized tissue specificity, have been 
identified in mammals. The physiological roles of CPT1A, the prominent CPT1 gene in liver, 
and CPT1B, the prominent CPT1 gene in muscle, are well established due to their role in 
pathogenicity. In contrast, the physiological role of CPT1C remains elusive.  
Although CPT1C expression is found in neurons throughout the entire brain, CPT1C 
expression is enriched in brain regions involved in the regulation of peripheral energy 
expenditure such as hypothalamus, amygdala and hippocampus. Hypothalamic feeding 
centers contain nutrient-sensitive neurons have been shown to regulate the desire for food 
intake and satiety in response to peripheral energy expenditure. The localization of CPT1C to 
brain, a tissue normally not using fatty acids as a primary energy source, suggests a 
potentially unique function for CPT1C. 
Cpt1c knock-out mice have been reported to have a reduced body weight on a normal diet, 
but when fed a diet that is rich in fats, these mice demonstrate an increase in relative body 
weight concurrent with a reduction in both food intake and insulin resistance. The expression 
of CPT1C in the hypothalamic feeding centers combined with the metabolic phenotype 
displayed by knock-out mouse suggest for a regulatory role of CPT1C in peripheral energy 
sensing and energy homeostasis.  
In addition to the role of CPT1C in normal brain, CPT1C has also been implicated in 
carcinogenesis. It has been demonstrated that CPT1C expression is induced by hypoxia and 
p53-stabilization. It has been shown previously, that CPT1C expression is increased in lung 
tumor samples if compared to normal tissue. Furthermore, cells depleted from CPT1C display 
a significant reduction in cell proliferation in response to hypoxia.  
The results presented here show that CPT1C expression is regulated by the presence of an 
upstream open reading frame (uORF) located the 5´UTR of the CPT1C mRNA. The presence 
of one or more uORFs is conserved in CPT1C mRNAs of different species but not within the 
CPT1 family of proteins. We showed that CPT1C expression is repressed by the presence of 
the uORF in the feeding state. This translational repression is released in response to reduced 
energy availability and AMPK activity. Our results furthermore show that the translation of 
the main ORF is also derepressed in response to Palmitate-BSA treatment. These results 
further support the hypothesis suggesting that CPT1C plays an important role in the nervous 
system control of energy homeostasis and peripheral energy expenditure although the 
involved signaling cascades still need to be established. 
We observed that CPT1C expression was also induced in response to HIV infection. HIV has 
been shown to remodel the host cell mechanism to facilitate virus production, which leads to 
increased β-oxidation rates. Induction of CPT1C expression in response to virus infection 
might be used to remodel cell metabolism in order to facilitate the production of new viruses. 
Furthermore, we were able to show that the induction of CPT1C in response to hypoxia was 
mediated by the Hypoxia-inducible factor (HIF) and that CPT1C expression correlates with 
the HIF target PGK in pediatric brain tumors. We showed that constitutive expression of 
CPT1C results in increased levels of cell proliferation and motility in established breast and 
brain cancer cell lines. Down regulation of CPT1C using shRNAs reduced cell proliferation 
and motility. In contrast to the metastatic phenotype that was observed under normoxic and 
hypoxic conditions, the reduction in cell proliferation was only in response to hypoxia. 
Cancer cell proliferation and metastasis in the hypoxic zone of solid tumors are mainly 
controlled by the HIF transcription factor complex. Induction of CPT1C expression in 
response to tumor hypoxia might present a survival mechanism for hypoxic tumor cells. Our 
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results add further evidence to the hypothesis that CPT1C contributes to metabolic adaptation 
of tumor cells in response to hypoxia. Activation of CPT1C in response to tumor hypoxia 
might lead to the activation of downstream pathways that serve to protect the cancer cells 
from metabolic stress. Further studies are necessary to establish the molecular function of 
CPT1C and the underlying signaling cascades. 
Understanding the role of CPT1C in cancer cell metabolism might lead to the development of 
new approaches for the treatment hypoxic tumors.  
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Die Carnitine Palmitoyltransferase 1C (CPT1C) wurde kürzlich als p53-induziertes, 
hirnspezifisches Mitglied der Carnitine Palmitoyltransferase (CPT) 1 Familie identifiziert. Die 
Mitglieder der CPT1 Familie regulieren den Import von Fettsäuren in die Mitochondrien und 
sind der limitierende Schritt der Fettsäureoxidierung. 
Die physiologischen Funktionen der Leberisoform CPT1A und der Muskelisoform CPT1B 
sind aufgrund ihrer Beteiligung an der Entstehung von metabolischen Krankheiten gut 
beschrieben. Im Gegensatz dazu ist die Funktion der Hirnisoform bisher noch ungeklärt.  
CPT1C konnte in den Neuronen des gesamten Hirnes nachgewiesen werden. Die höchste 
Konzentration findet sich aber in Hirnarealen welche mit der Regulierung der 
Nahrungsaufnahme und des Sättigungsgefühls assoziiert sind. Dazu gehören unter anderem 
der Hypothalamus, die Amygdala und der Hippocampus.  
Die Expression von CPT1C im Gehirn, einem Gewebe welches normalerweise Fettsäuren 
nicht als primäre Energiequelle verwendet, deutet auf eine einzigartige Funktion für CPT1C 
hin. Frühere Studien zeigen das Cpt1c defiziente Mäuse ein reduziertes Körpergewicht haben 
wenn sie mit einer normalen Diät gefüttert werden. Werden diese Mäuse aber mit einer 
fettreichen Diät gefüttert, zeigen sie eine signifikante Gewichtzunahme in Kombination mit 
reduzierter Nahrungsaufnahme und Insulin Resistenz. Die Expression von CPT1C in 
Hirnarealen welche die Nahrungsaufnahme regulieren und der metabolische Phänotyp der 
Cpt1c defizienten Mäuse implizieren eine regulatorische Rolle innerhalb der Regulierung der 
Energie Homeostase für CPT1C. 
Zusätzlich zur physiologischen Funktion im Gehirn, ist CPT1C auch mit der Krebsentstehung 
in Verbindung gebracht worden. Es wurde gezeigt, dass CPT1C Expression durch Hypoxie 
und p53 Stabilisierung induziert wird. Zusätzlich haben Studien gezeigt das CPT1C 
Expression in Lungentumoren im Vergleich zum Normalgeweben deutlich erhöht ist. CPT1C 
defiziente Zellen zeigen eine Reduktion der Zellteilung unter hypoxischen Bedingungen. 
Die hier vorgestellten Resultate zeigen das die Expression von CPT1C durch die Anwesenheit 
eines upstream open reading frames (uORF) in der 5´UTR reguliert wird. Die Präsenz von 
einem oder mehreren uORFs konnte in den CPT1C mRNAs von verschiedenen Säugetieren 
nachgewiesen werde, jedoch nicht in den mRNAs der anderen CPT Isoformen. Unsere 
Resultate zeigen dass die Translation der CPT1C mRNA durch die Präsenz des uORFs 
inhibiert wird. Die Translation der CPT1C mRNA wird durch eine Reduzierung der 
Energiezufuhr und die Aktivität von AMPK aktiviert. Zusätzlich wird die translationelle 
Inhibierung auch durch die Zufuhr von Palmitat-BSA aufgehoben. 
Diese Ergebnisse unterstützen die Hypothese, das CPT1C eine wichtige Rolle in der 
Regulierung der Energie Homeostase und des peripheren Energieverbrauchs durch das 
Nervensystem spielt. Die Signalkaskaden welche in diese Regulierung involviert sind, müssen 
durch weitere Studien etabliert werden.  
Außerdem haben wir beobachtet dass die Expression von CPT1C durch die Infektion mit HIV 
induziert. Frühere Studien zeigen dass die Infektion mit HIV zu gravierenden Änderungen im 
Zell Metabolismus führt, welche die Produktion von neuen HIV Viren zu ermöglichen. Die 
Veränderungen im Zell Metabolismus führen zu einen Aufregulierung der Fettsäure 
Oxidation. Die Induktion der CPT1C Expression kann dabei einen Weg zur Umstellung des 
Metabolismus nach der HIV darstellen. 
Die Expression von CPT1C wird außerdem durch die Stabilisierung von HIF induziert. In 
pädiatrischen Hirntumoren koreliiert die Expression von CPT1C mit der Expression von PGK 
eines HIF-induzierten Genes welcher als Marker für die Tumorhypoxie dient. 
Die Überexpression von CPT1C in etablierten Brust und Hirn Tumor Zelllinien führt zu 
verstärkter Zellproliferation und Zellmobilität. Die künstliche Reduzierung von CPT1C durch 
shRNAs führt zu einer Reduction von Zellproliferation und Motilität. Im Gegensatz zum 
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metastatischen Phänotyp wurde die Reduktion der Zellproliferation unter hypoxischen 
Bedingungen beobachtet. Tumorzellproliferation und Metastasierung in den hypoxischen 
Zonen solider Tumore werden hauptsächlich durch den HIF-Transcriptionskomplex reguliert. 
Die Hypoxie-induzierte Anreicherung von CPT1C könnte eine Möglichkeit darstellen das 
Überleben von hypoxischen Tumorzellen zu ermöglichen. 
Unsere Ergebnisse unterstützen die Hypothese, dass CPT1C zur metabolischen Anpassung 
von hypoxischen Tumor Zellen beiträgt. Die Induktion der CPT1C Expression durch Tumor 
Hypoxie könnte zur Aktivierung von Signalwegen führen, die Tumor Zellen vor 
metabolischem Stress schützen.  
Weitere Studien sind nötig, um die molekulare Funktion von CPT1C und die dem Phänotyp 
zugrundeliegenden Signalkaskaden etablieren.  
Eine tiefere Einsicht in die Rolle von CPT1C im Tumorzellmetabolismus könnte zur 
Entwicklung von neuen Therapieansätzen für die Behandlung von hypoxischen Tumoren 
führen. 
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µM   micro Mol 
ACC   Acetyl-CoA-Carboxylase 
AICAR  Aminoimidazol-Carboxamid-Ribonucleosid 
AMP   Adenosinmonophosphate 
AMPK   AMP-activated protein kinase 
ASN   Asparagine 
ATCC   American Type Culture Collection  
ATG   start codon 
ATP   Adenosine-5'-triphosphate 
BM   basement membrane 
BSA   bovine serum albumin 
CACT   Carnitine Acylcarnitine Translocase 
cDNA    complementary DNA 
cGy    centi-gray 
CNS   central nervous system 
CoA   Coenzyme A 
CPT1    Carnitine Palmitoyltransferase 1 
CPT1A  Carnitine Palmitoyltransferase 1 liver isoform 
CPT1B  Carnitine Palmitoyltransferase 1 muscle isoform 
CPT1C  Carnitine Palmitoyltransferase 1 brain isoform 
CPT2   Carnitine Palmitoyltransferase 2 
CMV   Cytomegalovirus 
CNS    Central Nervous System  
DMEM                       Dulbecco's Modified Eagle Medium 
DMOG  dimethyloxaloylglycine 
DNA   deoxyribonucleic acid 
DPP   dose per pulse 
DR   dose rate 
DSB   double strand break 
ECL   enhanced chemiluminescence reaction 
ECM   extracellular matrix 
EM   electron microscopy 
FA   fatty acid 
FAD   flavin adenine dinucleotide 
FAO   fatty acid oxidation 
FAS   Fatty Acid Synthetase 
FBS   fetal bovine serum 
FFA   free fatty acid 
FFF   flattening filter free 
GAPDH  Glycerinaldehyd-3-phosphat-Dehydrogenase 
GBM   glioblastoma multiforme 
GFP   green fluorescent protein 
Gy   gray 
H&E stain  hematoxylin and eosin stain 
HDAC   Histone Deacetylases 
HFD   high fat diet 
HIF   Hypoxia-inducible factor 
HIV   human immunodeficiency virus 
HNPCC  hereditary nonpolyposis colorectal cancer 
9 
Abbreviations 
10 
HRP    horse raddish peroxidase 
I.P.   intraperitoneal injection 
IR   ionizing radiation 
LCFA   long chain fatty acid 
LMNA  Lamin A 
LTR   long-terminal repeat 
MCD   Malonyl-Decarboxylase 
Min   minute 
mORF   main ORF 
M   mol 
mRNA  messanger RNA 
MU   monitor units 
NAD+   nicotinamide adenine dinucleotide 
NCBI   National Center for Biotechnology Information 
NFB   nuclear factor kappa-light-chain-enhancer of activated B cells 
ORF   open reading frame 
PCNA   Proliferating Cell Nuclear Antigen 
PCR    polymerase chain reaction 
PGK   Phosphoglycerate Kinase 
PHD   Prolyl-4-Hydroxylase 
PPAR   peroxisome proliferatoractivated receptors 
PRF   pulse repetition frequency 
PRO   prolin 
PVDF   polyvinylidene difluoride 
qRTPCR  quantitative real time PCR 
RNA   ribonucleic acid 
RLU   relative luciferase units 
S.C.    subcutaneous injection 
SCFA   short chain fatty acid 
SD   standart deviation 
SDS    sodium dodecyl sulfate 
shRNA  short hairpin RNA 
shRNAmir  microRNA-adapted shRNA 
SREBP  sterol regulatory element-binding protein 
uATG    upstream ATG 
uORF   upstream ORF 
UTR   untranslated region 
VEGF   Vascular Endothelial Growth Factor 
VHL   von Hipple-Lindau 
VSV   vesiculo-stomatitis virus 
WHO   World Health Organization 
wt   wild type 
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1.1 Cancer 
 
Cancer is, after cardiovascular diseases, the second leading cause of death world wide 
(WHO).  
In Switzerland over one quarter of all death cases during the last decade were caused by 
cancer (WHO). In Europe Lung cancer is the leading cause of cancer death in adults while 
leukemia is the most common cancer in children (WHO). The incidence of particular cancers 
varies around the world and sometimes according to the ethnic group. Over the next decades 
the incidence of various cancer types will dramatically increase due to an aging population 
and the maintenance of an unhealthy lifestyle. While it is well established that main risk 
factors for cancer development are genetic predisposition and the exposure to cigarette smoke, 
alcohol abuse and environmental toxins like asbestos and pesticides, the impact of wrong 
eating habits and obesity still need to be fully established. Risks to humans from carcinogens 
depend upon the dose and susceptibility. Factors influencing the susceptibility to cancer 
include age, sex, nutritional status and genetics. All cancers result from mutations of genes 
that allow the cells to begin an uncontrolled growth. These mutations can be either inherited 
or acquired. Only 5% of all cancers in Europe are thought to be explained by inherited genetic 
mutations. Known genes associated with hereditary cancer include the mutated BRCA1 and 
BRCA2 genes that increase breast cancer risk (50) and the HNPCC gene that is linked to 
colon cancer (221). Acquired mutations are caused by repeated exposure to carcinogens. The 
most significant avoidable carcinogens are chemical components like asbestos, pesticides or 
tobacco smoke. Dietary components, like excessive consumption of alcohol or of foods high 
in fat have also been linked with various cancers. These cancers also account for most of the 
cancer-related deaths due to the high amount of occurrence and malignancy. 
Additionally, infections with various pathogens are also known to cause cancer. The 
bacterium Helicobacter pyloris, for example, is known to cause ulcers and thereby increase 
the risk of stomach cancer (National Cancer Institute). Furthermore, several viruses, like 
members of the herpes virus group, human papilloma viruses and the human 
immunodeficiency virus, have been shown to be involved in the development of numerous 
cancers. 
There is usually a latency period of years or decades between exposure to a carcinogen and 
the appearance of cancer. This, combined with the individual nature of susceptibility to 
cancer, makes it very difficult to establish a cause for many cancers (168, 225). 
 
1.1.1 Tumor development 
 
Most DNA damages induced by carcinogens come to nothing because of the cellular DNA 
damage repair pathways that in normal cell repair any occurring DNA damage. Repeated 
exposure to DNA-damaging agents however can result in mutations or altered gene 
expression in so-called oncogenes and tumor-suppressor genes. Oncogenes mostly produce 
growth factors that activate signaling cascade that allow a cell proceed through the cell cycle 
and finally divide. Tumor suppressor genes on the other hand encode for factors that lead to 
the activation of signaling cascades that regulate for example cell cycle checkpoints, DNA 
damage repair or apoptosis. While mutations in oncogenes can lead to an activation of growth 
signaling cascades resulting in abnormal cell proliferation without exogenous signals, 
mutation in tumor suppressor genes allow the proliferation of damaged cells and thereby 
leading to further acquisition of mutations, neoplastic transformation and finally tumor 
formation. Although the signaling cascades involved in the neoplastic transformation of 
tumors cells can vary in different tissues, the underlying concept remains the same. 
11 
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In many cases the tumor remains small and 
localized for years, but after some time 
eventually begins to grow and spread. 
It is well established that tumor cells have to 
acquire the same six hallmarks to establish a 
tumor (Fig. 1). The order, in which these 
hallmarks are acquired, however, can vary 
significantly between different tumor types 
(32). Furthermore, the mutations needed in 
order to acquire the hallmarks can not only 
vary between tumor types but also between 
individuals having tumors of the same type. 
One of these hallmarks is the self-sufficiency 
in growth signals. Cells within healthy 
tissues only divide if they receive growth 
signal from other cells. These signal are 
detected by growth factor receptors such as 
the vascular endothelial growth factor  
 
Figure 1: The Hallmarks of cancer.  
This model defines the six common properties that tumors acquire to survive and metastasize. 
Adapted from Hanahan & Weinberg (2000) The Hallmarks of cancer. Cell 100: 57-70 
 
 
receptor. In response to ligand binding these receptors activate signal cascades stimulating 
cell proliferation and inhibiting apoptosis. Tumor cells in contrast do not depend on the 
stimulation of cell proliferation by exogenous growth signals. This can be achieved by a 
number of different approaches. Tumor cells can reduce the dependency on exogenous growth 
factors on the one hand by the endogenous production of growth signals and on the other hand 
by the modification of the total amount and activity of the growth factor receptors. Mutations 
that render the receptors constitutively active, leads to the activation of signal transduction 
pathways even in the absence of mitogenic factors. Additionally, tumor cells show 
modifications of the cytoplasmic components that regulate cell proliferation. Mutations of 
intracellular factors such as Ras, which is mutated in around 20% of all tumors, lead to the 
permanent stimulation of proliferation.  
 
1.1.2 Tumor hypoxia 
 
All solid tumors independent of their origin contain areas of low oxygen tension. Solid tumor 
growth is limited by the tumors potential to induce the intratumoral development of blood 
vessels. Without tumor vascularization tumor size is limited to a diameter of around 2mm. 
Tumor hypoxia occurs at a distance of 100-200µm from the blood vessel. Cells that are not 
able to adapt to the hypoxic conditions and survive the oxygen and nutrition deprivation will 
undergo apoptosis.  
Normal cells and tumors need oxygen to generate energy and to enforce most of the 
fundamental processes driving cell proliferation and survival. In tumor cells nevertheless, 
hypoxia is also strongly associated with tumor progression and metastasis (36, 91, 119, 121, 
125, 130, 144, 161). 
It is well established that tumor hypoxia induces an epigenetic selection for cancer cells that 
survive in the hostile tumor environment (119, 121, 125, 130, 159, 218). Emerging evidence 
suggests that the effect of hypoxia is controlled by Hypoxia-inducible factor (HIF) -mediated 
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activation of pathways which enable tumor cells to survive or escape their oxygen-deficient 
environment (91, 119, 121, 125, 130, 144, 159, 170).  
Under normoxic conditions HIF1 is unstable and rapidly degraded after protein translation. 
HIF1 stability is regulated by two prolines in the HIF1 oxygen-dependent degradation 
domain that are hydroxylated under normoxic conditions by a family of oxygen-dependent 
prolin hydroxylases (PH) and subsequently ubiquitinylated by the von Hipple-Lindau tumor 
suppressor. In response to hypoxia HIF1 is stabilized and associates with the ubiquitously 
expressed -subunit. Binding of transcriptional co-activators such as p300 activates the 
transcription of a growing number of genes containing hypoxia-responsive elements (Fig. 2). 
HIF induces the transcription of a growing number of target genes that mediate a wide range 
of cellular processes such as angiogenesis, glycolysis, cell proliferation, cell survival and cell 
death (65, 69, 88, 91, 119, 121, 122, 125, 127, 130, 170). 
It has been suggested by earlier publications that HIF plays an important role in 
carcinogenesis. This is supported by the fact that HIF is activated in the majority of human 
cancers, where it is mainly expressed in the hypoxic zones. Additionally, most HIF target 
genes found in hypoxic tumors are strongly associated with cancer progression and 
metastasis. In tumor cells HIF promotes the selection and expansion of more aggressive 
clones with a reduced apoptosis potential. This may explain why hypoxic tumor cells are 
mostly resistant to therapeutic approaches. In tumor cells HIF influences the tumor cell 
phenotype by activating key regulators of angiogenesis (91, 127), metastasis (91, 121, 144, 
161) and energy metabolism (86, 91, 121, 125, 130, 159, 225). 
 
 
 
 
Figure 2: Regulation of HIF stability by cellular oxygen availability. 
Under aerobic conditions, HIF is hydroxylated on proline 402 and proline 564. The proline 
hydroxylations are necessary for binding to von Hippel-Lindau (VHL) and ubiquitin-mediated 
degradation by the proteasome. The asparagine hydroxylation prevents binding to p300. 
Under hypoxic condition, HIF is stabilized binds to HIF and p300 and transactivates the 
transcription of hypoxia responsive genes. 
Adapted from: Schofield et al. (2004) Oxygen sensing by HIF hydroxylases. Nature Reviews Molecular Cell 
Biology 5: 343-354 
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Pharmacological inhibitors that block HIF signaling or HIF target genes such as VEGF have 
been proven to be successful cancer therapeutica (105). The identification of novel HIF target 
genes involved in tumor progression will lead to a better understanding of the molecular 
pathways involved in HIF-promoted selection of aggressive cancer cells and might thereby 
suggest new approaches for cancer therapy. 
 
1.1.3 Metabolic adaptation of tumor cells 
 
Cancer cells have different metabolic demands than normal cells to meet the requirements of 
rapid cell proliferation as well as autonomous growth and survival in an environment absent 
of contact with extracellular matrix. It is well established by a number of studies that the 
metabolic adaptation is required to support the proliferation of cancer cells. During 
carcinogenesis, cells acquire mutations that confer selective advantages for the growth of the 
tumor. It is hypothesized that most of the known oncogenes and some tumor suppressor genes 
regulate pathways and downstream target genes that are connected to the metabolic 
regulation. 
In most tumor types the rate of glucose uptake is increased while the rate of oxidative 
phosphorylation in mitochondria is reduced if compared to normal tissue. This effect is called 
aerobic glycolysis or Warburg effect (120, 130, 159, 209). It is well established that HIF 
activates angiogenesis to improve oxygen and nutrient supply in hypoxic tumors. Additionally 
the switch from oxidative phosphorylation to anaerobic glycolysis is a key player in the 
adaptive response to tumor hypoxia. HIF1 is the major transcription factor for the induction of 
most of the genes encoding glucose transporters and glycolytic enzymes (130, 159, 209) 
under hypoxic conditions. 
Glucose is transported into the cell by glucose transporters, which compromise six isoforms 
that differ in tissue specificity and kinetic behavior regulating the tissue capacity of glucose 
uptake and utilization. Following glucose uptake, tumor cells convert glucose to pyruvate by 
aerobic glycolysis. Pyruvate is finally converted into lactate instead of undergoing oxidative 
phosphorylation through the citric acid cycle. Lactate dehydrogenase, a direct target of HIF1, 
is the enzyme responsible for the conversation of pyruvate to lactate by facilitating the 
glycolytic flux and maintaining the NADH/NAD+ ratio under conditions of low oxygen. 
Earlier studies have demonstrated that HIF activation in hypoxic tumor cells correlates with 
increased glycolysis rates resulting in restored ATP levels and thus tumor growth (120, 125, 
130, 159, 209, 218). 
Although the metabolic adaptation of tumors is believed to mainly function through the 
glycolytic pathway, increasing evidence suggests the involvement of fatty acid oxidation 
(FAO) in this process (89, 102, 218, 222). 
It has been reported that some fatty acids play a role in enhancing cell proliferation and 
represent an important energy source in slow growing hepatomas (232) and prostate cancer 
(102). On the other hand studies done in colon cancer cells revealed that an increase in 
carnitine-dependent fatty acid uptake into mitochondria induces apoptosis.  
These studies show that the metabolic adaptation of tumors cells is not limited to changes in 
glycolysis and oxidative phosphorylation. Further studies are needed to elucidate the impact 
of FAO in the metabolic adaptation in cancers of different origins. 
 
1.1.4 Metastasis 
 
Metastasis represents the final and fatal stage of cancer and is the leading cause for cancer 
related death. In spite of the significant improvement of cancer prevention and early detection, 
a high number of tumors already gave rise to distant metastasis or are in the process of 
spreading at the time of diagnosis (WHO). 
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The process of cancer cell invasion and metastasis and the molecular mechanism underlying 
this process, although accounting for 90% of cancer deaths (WHO), are still insufficiently 
understood. 
Once the primary tumor has formed up to 1 million cells can leave the tumor mass per day 
and enter the metastasis cascade. Fortunately the metastatic process is not very efficient. Due 
to that the amount of metastasis which evolves into a clinical disease is relatively low. 
Furthermore it has been demonstrated by clinical studies that the metastatic potential not only 
depends on tumor type and grading but also on the immunological status of the patient. 
Tumor invasion and metastasis through the bloodstream to an anatomically distant side is a 
coordinate multistep process that involves the activation of complex signaling cascades (54, 
100, 173, 187, 190, 201, 203, 217).  
The metastatic cascade can be dived into four major steps: (1) the release of tumor cells from 
the primary tumor mass, (2) invasion of the basement membrane (BM) and migration through 
the extracellular matrix (ECM) surrounding the tumor mass and subsequent invasion of the 
basement membrane of the endothelium in order to allow intravasation, (3) adhesion to the 
endothelial cells and extravasation, (4) and finally colonization of the tissue and tumor cell 
proliferation (Fig. 3). Prior to the actual activation of the metastatic cascade, the tumor has to 
activate angiogenesis to allow the development of new vessels to increase the blood supply of 
the growing tumor. Without the formation of intratumoral vessels a tumor would not be able 
to grow beyond 2mm of diameter and in addition it is well established that the metastatic 
cascade can not be activated without the formation of blood supply to the primary tumor.  
Cancer cells must become motile in order to leave the primary tumor and move to the 
metastatic side. The first step of this process is the disaggregation of tumor cells from the 
primary tumor mass which results from a loss of cell-cell-adhesion mediated by altered 
expression of adhesion molecules like cadherins and catenins (51, 100, 103, 145, 152, 173, 
181, 187, 190, 217). 
 
 
Figure 3: The metastatic 
cascade. 
(1) De-adhesion of tumor cells 
from the primary tumor, (2) 
migration through the ECM and 
intravasation, (3) adhesion of 
tumor cells to the endothelial 
cells and extravasation, (4) 
proliferation of tumor cells and 
establishment of a distant 
metastasis 
Adapted from Gomez et al. (2004) 
Potential application of desmopressin 
as a preoperative adjuvant in cancer 
surgery. Biological effects, antitumor 
properties and clinical usefulness. 
Cancer Therapy 2: 279-290 
 
 
After overcoming the adhesive constraints, the cells have to invade and migrate through the 
BM and ECM to intravasate the vessel. This is facilitated by the expression of proteolytic 
enzymes such as Matrix-Metalloproteases that degrade matrix proteins and thus allow the 
invasion through the stroma. Upon physical contact between tumor and endothelial cells 
mediated by integrins, the endothelial cells retract and allow the tumor cells to enter the blood 
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circulation. Once in the circulating system the tumor cells have to adapt to the shearing forces 
generated by the blood flow and evade attacks from the immune system. When the tumor 
cells reach the capillary bed of the target organ they attach to the endothelial cells, stimulate 
endothelial retraction and invade the target organ.  
A critical step in the formation of distant metastasis is the adaption of tumor cells to the new 
microenvironment after extravasation. Tumor cells might depending on the primary tumor 
type and aggressiveness either undergo apoptosis, remain dormant or start proliferating 
immediately. Only a very small portion of the cells that enter the circulating system will 
succeed in forming a metastasis in the secondary tissue. 
Tumor cell invasion is widely influenced by the tumor microenvironment. Hypoxic conditions 
within the primary tumor mass activate signaling cascades that stimulate cancer cells 
spreading by altering gene expression through hypoxia-responsive proteins like HIF1. HIF1 
transcriptionally activates genes involved in the activation of the metastatic cascade (91, 121, 
125, 144, 161, 187) in order to ensure cell survival (227). The molecular mechanism by which 
tumor hypoxia might induce tumor cell migration are not fully elucidated yet. Nevertheless, 
increased mutation rates, genomic instability and a strong epigenetic selection for cancer cells 
that survive the hostile tumor environment are likely to be involved in this process (144, 181, 
190, 219). 
 
1.1.5 Breast cancer 
 
Breast cancers can occur in men and women but are mostly found in women, where they are 
the most prevalent cancer as well as the leading cause for cancer death.  
Breast cancers originate from breast tissue, most commonly from the milk ducts or the lobules 
that supply the ducts with milk. There are many different types of breast cancers, with 
different stages and aggressiveness. Breast cancers can spread to almost any area of the body. 
The most common regions that breast cancers may spread to are bone (25%), lung (21%), 
liver (15%) and brain (5%) (87, 205).  
Patient survival varies from 98% to 10% depending on tumor stage and treatment. Due to 
today’s prevention strategies leading to earlier tumor detection and the improvement of breast 
cancer therapy, the survival rates have markedly improved. Metastasis occurring in the later 
stages nevertheless represents the most serious thread for patient survival (205). 
 
1.1.6 Brain cancer 
 
There are two types of brain tumors: primary brain tumors that originate in the brain and 
secondary brain tumors that originate from cancer cells that have migrated from other parts of 
the body.  
Primary brain tumors are divided into nine categories, which are based on the types of cells in 
which the tumors originate. Gliomas are primary brain tumors that are made up of glial cells 
which provide important structural support for the nerve cells in the brain. All gliomas range 
from well-differentiated low grade tumors to anaplastic high grade tumors. Anaplastic tumors 
independent of the cellular origin are completely undifferentiated, chaotic tumors that are 
highly aggressive and associated with low survival rates (26, 61, 68, 192).  
Primary brain tumors although rarely spreading beyond the central nervous system (CNS), 
spread within the brain tissue and death is induced by tumor growth within the limited space 
of the skull. 
Secondary brain cancers occur in 20–30% of patients with metastatic disease and the 
incidence increases with age. Generally brain cancer metastasis occurs only in the advanced 
disease and has a poor prognosis (150, 213). 
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Glioblastoma multiformae, which represent 23% of all brain tumors, are among the most 
malignant human cancers with a five-year survival rate of 4.9% in patients older than 50 
years. Following a short period of remission, the tumors almost always recur and the patient 
succumbs to the fast progressing disease.  
Though intensive research has been done on brain cancers over recent years, the prognosis for 
brain cancer patients has hardly improved. Histological tumor staging and patient therapy are 
still limited due to missing molecular markers that would allow a prediction of tumor 
aggressiveness and its sensitivity to therapy (181, 202, 204, 212). 
 
1.1.7 Cancer treatment 
 
Cancer therapy is mainly based on three treatment modalities: surgery, chemotherapy and 
radiotherapy. Apart from that, new cancer treatments like antibody- and hormone-based 
approaches are continuously developed and tested in clinics (105, 167, 194). 
If allowed by tumor type, location and patient health, the tumor and surrounding infiltrated 
tissue is removed by surgery. Either in addition to surgery or as a replacement, most tumors 
are treated with radio- and/or chemotherapy.  
Chemotherapy provides a systemic approach for cancer therapy. Most therapeutic drugs 
poison cells by either impairing cell division or metabolism and thereby effectively kill fast-
dividing cells. Because chemotherapy mainly affects cell division, tumors with high growth 
fractions such as aggressive lymphomas are more sensitive to chemotherapeutic drugs than 
slow growing tumors such as slow growing lymphomas (40, 77). 
Due to its systemic administration, chemotherapy not only impacts on tumor cells but also 
affects fast dividing healthy cells like hematopoietic cells, hair follicles and intestinal cells. 
Further studies are necessary to identify new drug targets that allow the specific elimination 
of tumor cells and yet display low side effects. 
Radiotherapy represents one of the most effective tools in the treatment of human cancers. In 
contrast to chemotherapy, radiotherapy allows the local application of the ionizing radiation 
(IR) and thereby avoiding the systemic side effects induced by chemotherapy. Linear 
accelerators used for patient treatment allow the fast and precise irradiation of tumors located 
in virtually any part of the human body (188). 
It is well established that cells exposed to IR show DNA lesions, increase mutation rates, 
chromosome aberrations and finally apoptosis. DNA damage induced by IR arises not only 
from direct effects but is also induced by reactive oxygen species derived from water 
hydrolysis. Although IR induces a number of different DNA lesions, DNA double strand 
breaks (DSB) are the most damaging DNA lesion because of their impact on genome stability 
and proliferation (1, 31, 74, 92, 193, 208). Once detected DNA damages are repaired by 
specific DNA damage repair pathways that utilize different set of proteins depending on the 
induced DNA lesion. Furthermore, signaling cascades that slow or arrest the cell cycle are 
induced to delay cell cycle progression until the damage is repaired. If the lesion can not be 
repaired, pro-apoptotic pathways are induced to remove the damaged cells from the 
proliferative pool. 
Although today’s cancer therapies allow the efficient elimination of tumor cells, some tumor 
types for example glioblastomas are still mainly resistant to therapy. The same is true for 
hypoxic tumors which represent a serious tread to patient survival because of the high rate of 
surviving tumor cells and the ability of tumor hypoxia to induce pathways leading to 
metastasis (40, 71, 77, 127, 193, 196, 202). New approaches are needed to render hypoxic 
cells sensitive to cancer therapy. 
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1.2 Regulation of gene expression 
 
Physiological processes important in cell growth and metabolism as well as stress-induced 
pathways depend on the regulation of gene expression. This regulation can occur on various 
levels from the regulation of gene transcription to the regulation of protein stability (Fig. 4). 
The regulation of transcription, which is working through a canopy of transcription factors, is 
well studied and understood (12, 30, 47, 233, 234). A determination of the mRNA level, 
however, is not predictive for the level of the encoded protein (35). Gene expression is further 
regulated at the step of RNA processing and translational initiation to allow the modulation of 
translation efficiency and RNA stability (3, 12, 14, 30, 37, 152). It is important that this multi-
step process is tightly controlled to ensure that all steps function in a concerted manner. 
Specific signal cascades are used to regulate each step of gene expression to integrate cellular 
and environmental signals. 
 
Figure 4: The regulation of gene expression. 
Adapted from: Essential Cell Biology, Second Edition, Garland Publishing 
 
 
1.2.1 Transcriptional regulation of gene expression 
 
The transcriptional regulation of gene expression controls which gene is transcribed, when 
transcription occurs and how much of a certain mRNA is transcribed. mRNA transcription is 
regulated by a number of mechanisms such as the regulation of histone remodelling, the 
regulation of transcription factor expression and stability, and the use of transcriptional 
enhancers and repressors (233, 234). 
Histon proteins assemble with the DNA to form nucleosomes which consists, the basic 
repeating unit of chromatin. The nucleosome contains 146bp of DNA wrapped around a 
protein core consisting of each two copies of the four histone proteins H2A, H2B, H3A and 
H4. Untranscribed regions are packed into highly condensed heterochromatin while 
transcribed genes are packed into the more accessible euchromatin. The DNA of each cell 
type is packed into a unique pattern of hetero- and euchromatin determining the unique 
characteristics of each cell line. This pattern is maintained after cell division to transfer the 
lineage specific gene expression pattern to the next generation.  
To activate gene expression, transcriptional activators need to bind and remodel the chromatin 
structure to allow DNA accessibility. 
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Figure 5: The molecular apparatus controlling transcription. 
Four kinds of components control transcription in eukaryotic cells. Basal transcription factors 
bound to the TATA box-binding protein are the minimal requirement for RNA polymerase II 
recruitment and transcriptional initiation. Activators and repressors are regulatory sequence-
specific DNA-binding proteins that communicate with the basal transcription factors via co-
activators and act to regulate transcription efficiency. 
Adapted from Tjian R. (1995) Molecular Machines That Control Genes. Scientific American 272 (2): 54-61 
 
 
The transcription of most human genes is regulated by transcription factors that bind specific 
DNA regulatory sequences upstream of the core promotor. The activity of most transcription 
factors is controlled by regulatory signaling pathways that modulate transcription in response 
to diverse endogenous or exogenous signals. Transcription factors can either act as 
transcriptional enhancers or repressors. The action of a certain transcription factor can vary 
depending on the transcribed gene and cell type. The transcription factors bind to the 
regulatory elements and promote access to the DNA through interactions with other 
components of the transcription machinery. The transcription is initiated by the recruitment of 
the RNA polymerase II to the transcriptional start site by the basal factors (Fig. 5). After 
transcriptional initiation, a cap structure is added 5´to the newly synthesized transcript which 
serves as a binding site for proteins involved in mRNA export to the cytoplasm and 
translation. During transcription elongation, which is regulated by elongation factors, the 
polymerase moves 5´to 3´along the gene sequence and extends the transcript. During the 
elongation of the synthesized mRNA, non-coding sequences (introns) are removed by pre-
mRNA splicing. At the end of the gene, the transcription is terminated and the synthesized 
mRNA is cleaved and the PolyA tail is added 3´to the end of the transcript. After transcription 
and transcript processing, the mRNA is transported to the cytoplasm for translation. 
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The transcription of genes is influenced by the cell environment, metabolic status and cell 
lineage through the differential expression and activity of a multitude of transcription factors 
(88, 151, 229, 233). 
In addition to the role if fatty acids (FAs) as an energy source, FAs have been shown to affect 
gene expression of genes involved in the regulation cell proliferation, differentiation, 
metabolism and apoptosis. FAs regulate the transcription of target genes such as CPT1 and 
Acyl-CoA Synthetase via changes in activity or abundance of several transcription factors like 
PPAR, SREBP and NFB. The FA control of these transcription factors involves the direct 
binding of FA to the transcription factors or the indirect activation of transcription factors by 
the activation of FA-induced signaling cascades (9, 24, 41, 67, 214). Epigenetic changes 
induced by dietary FAs have been implicated in a number of diseases like coronary artery 
disease, insulin resistance, hypertension and cancer (24, 97, 109, 134, 177, 178). In cancer, 
FAs have been hypothesized to alter the expression of genes involved in cell growth, 
metabolism and adhesion and thereby contribute to cancer progression (102, 218, 220, 222). 
As mentioned earlier, hypoxia has profound influence on cellular gene expression. The main 
transcription factor involved in the hypoxia-dependent transcriptome remodeling is HIF (65, 
81, 88, 229). HIF is stabilized in response to hypoxia and leads to the transcription of target 
genes containing a hypoxia response element after polymerization with HIF and p300 (Fig. 
2). In addition, the HIF-binding protein p300 is a histone acetyl-transferase that plays an 
important role in the full activation of HIF-target gene transcription by modifying the 
chromatin structure (68, 81, 125). Interestingly, histone deacetylases (HDAC) have also been 
shown to be interaction partner of HIF (81, 125) and are associated with HIF transcriptional 
activity. Binding of HDACs to the HIF leads to protein stabilization by binding to the 
oxygen-dependent degradation domain (81, 122, 133). Activation of HIF-dependent 
transcription allows cell survival under hypoxic conditions (81, 91, 121, 130).  
Viruses are known to re-program cellular pathways to facilitate virus production. HIV 
infection of T lymphocytes leads to major changes in the transcriptome. It has been shown 
that HIV infection alters the expression of a number of transcription factors and genes 
involved in RNA processing in order to facilitate high HIV gene expression and virus packing 
(188). Changes in transcription factor expression and activity upon HIV infection have been 
shown to alter host cell metabolism by upregulation of -oxidation and down regulating 
glycolysis (168). Furthermore, some viruses have been shown to induce the oncogenic 
transformation of the infected cell as a side effect of cell programming (168, 188) and thereby 
induce carcinogenesis. 
 
1.2.2 Post-transcriptional regulation of gene expression 
 
Translational control as a tool to regulate gene expression has been found in many species 
(35, 36, 57, 59, 139, 181). In most species, posttranscriptional regulatory mechanisms have 
been shown to play an important role in stress response pathways (47, 57, 78, 98, 110, 149, 
160, 182, 206) and lead to dysfunctional regulatory pathways if blocked by mutations (20, 46, 
104, 111, 132, 149, 153, 182).  
The posttranscriptional events compromise pre-mRNA processing, mRNA localization, 
stabilization (3, 37, 166) and translation (8, 35, 152). Each event is tightly regulated due to the 
impact that each step can have on mRNA translation. The mechanisms regulating each step, 
although poorly understood, involve mRNA structural components and mRNA binding 
proteins (51).  
Many of the mutations found in human cancers lead to truncated ORFs which reduces mRNA 
stability by the activation of the non-sense-mediated decay. Often mutations also affect 
mRNA splicing and generate alternatively splice mRNA which contain premature stop 
codons. Premature stop codons reduce mRNA stability by the induction of non-sense-
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mediated decay. Non-sense-mediated decay is induced by slice site markers that remain 
bound to the mRNA after the first round of mRNA translation (35, 166, 182). This effectively 
prevents the production of truncated protein. 
Post-transcriptional regulation of gene expression can also be controlled by short sequence 
elements located in the UTR´s of mRNAs. One of these elements found within the 5´UTR are 
upstream open reading frames (uORFs).  
The presence uORF within the 5´UTR is crucial for the translation initiation of the main open 
reading frame (mORF) (38, 158, 182). uORFs are defined by a start codon that is out of frame 
of the mORF and a length of at least 9nt. It has been shown that mRNAs can contain one or 
more uORFs that are either fully upstream or overlapping with the mORF (Fig. 6). The uORF 
is except for a few cases (182) not encoding for a protein.  
Because eukaryotic ribosomes generally only initiate once per mRNA (8), the presence of an 
uORF normally inhibits the translation of the mORF and may lead to mRNA decay (37, 153, 
182). Earlier studies showed that ribosomes loaded on the 5´cap of uORF containing mRNAs 
can either only translate the uORF or reinitiate and also translate the mORF (182). It has been 
shown that many stress-induced genes contain uORFs. In these mRNAs the uORF is 
translated under normal conditions, while if the cells are exposed to the specific cell stress the 
ribosomes either reinitiate after the uORF or simply scan through the uORF leading to the 
translation of the mORF (182). In all genes where uORF have been identified so far the mere 
presence of the uORF is sufficient for the regulation of the mRNA translation and mRNA 
stability.  
It has been estimated that approximately half of human protein-encoding genes contain 
uORFs (182), nevertheless, the impact of this post-transcriptional regulation mechanism on 
cellular signaling cascades is yet unsolved. Furthermore, the impact of RNA-binding proteins 
in this regulation needs further examination. 
Although they are usually short sequences, uORFs may still play critical roles in modulating 
physiology. Indeed, mutations that introduce new or disrupt existing uORFs have been 
reported to cause human diseases (20, 46, 104, 111, 182). Additionally, recent publications 
also implicate abnormalities in post-transcriptional regulation pathways in cancer 
development (28, 104, 132, 153). 
 
 
 
 
 
Figure 6: Schematic representation of a mRNA containing 2 uORFs in the 5´UTR. 
Adapted from Calvo et al. (2009) Upstream open reading frames cause widespread reduction of protein 
expression and are polymorphic among humans. PNAS 106, 7507-7512 
 
 
1.3 Hypothalamic regulation of peripheral energy homeostasis 
 
The maintenance of whole body energy homeostasis is critical for survival. This requires the 
presence of sensors that detect changes in whole body energy expenditure and induce adaptive 
responses. Nutrient-sensitive neurons are found in the brain stem and hypothalamus (52, 63, 
82, 93, 107). These regions play an important role in the nervous system control of energy 
homeostasis. Hypothalamic feeding centers have been shown to regulate the desire for food 
intake and satiety (29, 49, 52, 63, 82, 93, 107, 108, 117, 165). 
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The AMP-activated protein kinase (AMPK) has been shown to play an important role in the 
hypothalamic regulation of energy homeostasis. AMPK is a heterotrimeric kinase complex 
composed of a catalytic  subunit and two regularly  and  subunits. In mammals, several 
alternative genes for each subunit have been identified that display a cell and tissue type 
specific expression pattern. AMPK activity is enhanced by AMP binding and phosphorylation 
of the catalytic subunit by upstream kinases. 
Hypothalamic AMPK is responsive to alteration in cellular energy level, circulating hormones 
and nutritional cues (29, 44, 52, 63, 93, 117, 165, 224). The modulation of AMPK activity in 
response to these factors initiates signaling pathways leading to changes in feeding behavior 
(140, 165).  
Hypothalamic AMPK activity is tightly regulated under physiological conditions. Different 
studies showed that injection of mice and rats with leptin decreased AMPK activity and lead 
to a subsequent reduction in feeding behavior (44, 52, 63, 82, 97, 117, 140). This was also 
true for other anorexic stimuli such as insulin, glucose and refeeding after a fasting period 
(44, 52, 117). These results show that a reduction in hypothalamic activity is sufficient to 
reduce food intake and body weight (44, 52, 97, 146). In contrast to these results, injection of 
the pharmacological AMPK agonist AICAR or the expression of constitutively active AMPK 
cause an increase in food intake and body weight (44, 82, 97, 146). 
The molecular mechanism(s) by which AMPK regulates nutritional satiety involving the 
hypothalamus are still largely unknown but it may function through controlling differential 
hypothalamus gene expression.  
In addition to the AMPK-mediated regulation of energy homeostasis, FAs are also involved in 
the nervous control of energy homeostasis (49, 52, 56, 72, 82, 97, 118, 131, 134, 178). It has 
been shown that free FAs are not used as fuel for neurons but serve as informative molecules 
about the whole body energy homeostasis (49, 72, 82, 97, 113, 134). Specialized neurons 
within the hypothalamus detect variations of FA levels in the plasma and integrate this 
information in the regulation of peripheral glucose and lipid metabolism. Inhibition of the 
hypothalamic Carnitine Palmitoyltransferase 1 (CPT1), the enzyme that controls the entry of 
long-chain-fatty acids (LCFAs) into the mitochondria for -oxidation, by chemical inhibitors 
or the accumulation of LCFAs in the hypothalamus causes a reduction of food intake (49, 52, 
56, 97, 107, 108, 118). It has been hypothesized that high FA levels might serve as a signal 
for sufficient feeding and thereby reduce food intake. Further studies are needed to elucidate 
the mechanisms by which CPT1 inhibition regulates feeding behavior and to elucidate the 
neurotransmitters used by these neurons. 
 
 
1.4 -Oxidation 
 
LCFAs serve as an energy source for many tissues, especially heart and skeletal muscle. But 
some tissues like the brain, erythrocytes and adrenal medulla are not believed to utilize fatty 
acids for energy requirements.  
-oxidation is the process by which fatty acids are broken down in mitochondria and/or 
peroxisomes to generate Acetyl-CoA, the entry molecule for the Citric Acid cycle. 
Fatty acid oxidation involves three specific steps: (1) uptake and activation of FFAs, (2) 
translocation of fatty acyl-CoA into the mitochondria for (3) -Oxidation. 
After their entry into the cell through specific membrane transporters, FAs must be esterified 
to Coenzyme A (CoA) before they can undergo oxidative degradation. Acyl-CoA Synthetases 
located in the outer mitochondrial membrane catalyze the activation of LCFAs by esterifying 
them to Coenzyme A. In order to enter the mitochondria for -Oxidation, the FAs are 
conjugated to carnitine. This is facilitated by CPT1, which is located in the outer 
mitochondrial membrane with the active center facing the cytoplasm (17, 53, 210). The acyl-
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carnitine can freely migrate through the outer mitochondrial membrane and is then 
translocated through the inner mitochondrial membrane by the Carnitine Acylcarnitine 
Translocase (CACT) which exchanges one molecule long-chain acylcarnitine for one 
molecule of carnitine. Once inside the mitochondria the fatty acid is conjugated back to CoA 
while carnitine is released to the mitochondrial matrix. The generated fatty acyl-CoA enters 
-Oxidation (Fig. 7). 
Each cycle of -Oxidation occurs in a sequence of four reactions that reduce the FA chain 
length by a two carbon unit-acetyl CoA. The first step of -Oxidation is the dehydrogenation 
of the fatty acid by the Acyl-CoA-Dehydrogenase which catalyses the formation of a double 
bond between the C2 and C3. In the next step the bond between C2 and C3 is hydrolyzed in a 
sterospecific reaction leading to the formation of the L-isomer by the Enoyl-CoA-Hydratase. 
The L--hydroxyl-CoA is oxidized by NAD+ through the action of the L--hydroxyl-CoA-
Dehydrogenase which converts the hydroxyl group into a keto group. The final step is the 
cleavage of the -ketoacyl-CoA by the -ketothiolase resulting in an Acetyl-CoA molecule 
and an acyl CoA molecule that is two carbons shorter. The process is repeated until the entire 
chain is cleaved into acetyl CoA units. 14 ATP molecules are generated during every 
oxidation cycle. 
The generated Acetyl-CoA can enter the citric acid cycle where Acetyl-CoA is degraded to 
CO2. The citric acid cycle produces NADH and FADH2 which are subsequently used in the 
electron transport chain to produce ATP.  
Fatty acid oxidation also occurs in peroxisomes, when the fatty acid chains are too long to be 
handled by the mitochondria. It is believed that very long chain fatty acids undergo initial 
oxidation in peroxisomes until octanyl CoA which is followed by mitochondrial oxidation. 
In contrast to the mitochondrial -Oxidation, the FA oxidation in peroxisomes is not coupled 
to ATP synthesis. Instead, the electrons are transferred to O2, which yields H2O2. The enzyme 
catalase, found exclusively in peroxisomes, converts the hydrogen peroxide into water and 
oxygen. Peroxisomal β-oxidation also requires enzymes specific to the peroxisome and to 
very long fatty acids. 
 
1.4.1 The Carnitine Palmitoyltransferase system 
 
The Carnitine Palmitoyltransferase system allows the transfer of LCFAs into the 
mitochondria and is composed of three different proteins: CPT1, CPT2 and CACT each with 
different sub-mitochondrial localization (7, 103). Three CPT1 genes displaying tissue specific 
expression pattern have been identified in mammals. CPT2 and CACT are ubiquitously 
expressed throughout the tissues (7, 103). 
Deficiencies of the Carnitine Palmitoyltransferase system have been shown to be among the 
most common causes of inherited fatty acid oxidation disorders.  
CACT deficiencies present mostly in the neonatal periods with irregular heart beat, seizures 
and apnea, and are believed to be triggered by fasting or physiological birth stress. In these 
patients, free carnitine levels are extremely reduced while long-chain acylcarnitine levels are 
markedly increased (21, 59, 103). 
There are several CPT2 deficiencies described in the literature which can be classified 
according to the age of onset and tissue distribution of the symptoms. More than 40 mutations 
of the CPT2 gene locus have been reported to date (21, 59) which are distributed throughout 
the entire coding sequence. Most of the described mutations are missense mutation (77%) that 
interfere with the enzymatic activity thus with the level of LCFAs oxidation (21, 59). Indeed, 
studies have shown that the residual activity of CPT2 activity strongly correlates with the 
severity of the disease (11, 21, 59). Symptoms are usually triggered by physical exercise, 
infection and period of fasting and include muscle stiffness and weakness, myoglobinuria, 
liver failure and transient hepatomegaly (11, 21, 59, 103). 
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Figure 7: The Carnitine Palmitoyltransferase system. 
Upon import into the cell, the FFA is transported to the Acyl-CoA Synthetase where the FFAs 
is coupled to CoA. CPT1 transfers the fatty acyl group from acyl-CoA to carnitine to allow 
transport into mitochondria. The CACT exchanges one molecule long-chain acylcarnitine for 
one molecule of carnitine. CPT2 reverses the reaction of CPT1 to generate the substrate for -
Oxidation. 
 
 
In most of the Carnitine Palmitoyltransferase system deficiencies the therapy consist in the 
feeding of a diet rich in carbohydrates and low in fat and the prevention of periods of fasting 
(21, 103). 
CPT1A deficiencies are the only CPT1 deficiency found in humans. CPT1A deficiencies due 
to mutations of the gene locus are mainly diagnosed in young children after infections or 
periods of fasting. Symptoms of CPT1A deficiencies include an altered mental status, 
elevated levels of plasma carnitine and hepatomegaly with or without acute liver failure (59). 
Up to know no cases of CPT1B or CPT1C deficiencies have been described in the literature. 
CPT1B expression is crucial for heart function (59). Mutations of this isoform might therefore 
be incompatible with life (59). Deficiencies of the brain isoform CPT1C if compatible with 
survival might present as dysregulations in appetite control (59). 
Missregulations of CPT1 activity as a regulator of -Oxidation have additionally been 
implicated in the development of the metabolic syndrome (21, 43, 73, 143, 209). The 
metabolic syndrome is mainly characterized by obesity and the insensitivity to insulin 
signaling and represents a major health problem in our society. In addition to its impact on 
public health by the means of diabetes, wrong eating habits and obesity are also important 
factors in the development of some cancers.  
Apart from its role in regulating -Oxidation, CPT1A has also been implicated in cancer 
development through its link to apoptosis. Nuclear CPT1A expression has been demonstrated 
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in human tumors where it has been shown to interact with HDAC1. In this context, CPT1A 
might serve as a regulatory protein that recruits HDAC complexes to acetylated histones of 
specific genes to silence gene expression by histone hypoacetylation. This contributes to the 
silencing of tumor suppressor genes and facilitates carcinogenesis (133). 
 
1.4.2 The CPT1 family of proteins 
 
The CPT1 family of protein consists of three proteins that demonstrate a generalized tissue 
specificity. The three isoforms are encoded by genes located on different chromosomes. 
Although neither isoform has been isolated in a catalytically active form yet, the physiological 
roles of CPT1A, the prominent CPT1 gene in liver, and CPT1B, the prominent CPT1 gene in 
muscle, are well established primarily due to their role in pathogenicity (39, 48, 59).The 
physiological role of CPT1C, the CPT1 primarily expressed in brain tissues, however is not 
fully established yet.  
CPT1A is the most ubiquitous expresses CPT1 family member and is expressed in liver, 
pancreas, kidney, blood and brain. CPT1B is only expressed in heart, muscle and brown 
adipose tissue. CPT1C expression is limited to brain and testis.  
The topology of CPT1 within the mitochondrial outer membrane has not been rigorously 
examined because the tight association of CPT1 with the membrane inhibits the extraction of 
catalytically active CPT1. Nevertheless, studies have suggested that the catalytic domain and 
the regulatory malonyl-binding domain are both localized to the cytoplasmic site of the 
membrane (17, 53, 207). 
The control of -oxidation is manifested at the step of FA import into the mitochondria by 
regulating the transferase activity of CPT1 in response to the feeding state. CPT1 activity is 
mainly inhibited by the binding of the allosteric CPT1 inhibitor Malonyl-CoA to the 
regulatory subunit. During the fed state high insulin levels elevate the Malonyl-CoA 
concentration sufficiently to inhibit CPT1 activity resulting in a significant reduction in -
Oxidation. In the fasted state in contrast, the Malonyl-CoA level falls and CPT1 inhibition is 
reversed and -Oxidation is activated (2, 4, 6, 10, 43, 53, 73, 118, 143). Intracellular Malonyl-
CoA concentration is controlled by the activity of two enzymes. It is synthesized by the 
Acetyl-CoA-Carboxylase (ACC), the rate-limiting enzyme in malonyl CoA synthesis and 
degraded by the Malonyl-Decarboxylase (MCD). Decreases in the ATP/AMP ratio activate 
AMPK which phosphorylates ACC and inhibits both its basal activity and activation by 
citrate, the precursor of its substrate, linking cytosolic Malonyl-CoA synthesis directly to 
changes in the cellular energy state. Additionally, AMPK activation also leads to the 
phosphorylation and activation of MCD and subsequent Malonyl-CoA degradation. Due to 
this regulatory feedback mechanism Malonyl-CoA levels are highest in the fed state and 
rapidly fall during fasting. As a consequence of decreasing Malonyl-CoA levels CPT1 is 
reactivated and -Oxidation rates are increased. 
Despite the fact that the CPT1 isoforms are structurally similar, they display significantly 
different kinetic and regulatory properties. All CPT1 isoforms are inhibited by Malonyl-CoA 
binding. If compared to CPT1B, CPT1A displays a higher affinity for its substrate carnitine 
and a lower affinity for Malonyl-CoA (2, 6). The Malonyl-CoA binding efficiency of CPT1C 
is similar to the binding efficiency of CPT1A. The differences in Malonyl-CoA affinity are 
believed to be crucial for the function of different cell types by the modulation of tissue 
partitioning of fatty acid metabolism. 
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1.5 The Carnitine Palmitoyltransferase 1C 
 
Carnitine Palmitoyltransferase 1 (CPT1) C is an isoform of the CPT1 family that is expressed 
specifically in the brain where it is enriched in neurons of the hypothalamic nuclei (48). The 
fact that CPT1C is mainly expressed in the CNS (48, 64, 116, 176, 189), a tissue normally not 
using fatty acids as a major energy source, suggests a potentially unique function for CPT1C.  
 
1.5.1 CPT1C function in normal brain 
 
CPT1C expression in normal tissue is mainly localized to brain but has also been found in 
testis (48, 147). In brain, CPT1C expression is found in neurons throughout the entire brain 
but shows the highest level in neural feeding centers within the hypothalamus (147). Neurons 
in the hypothalamic feeding centers have been shown to be crucial in appetite regulation and 
the maintenance of whole body energy homeostasis. Hypothalamic CPT1C expression 
correlates with the expression of the Fatty Acid Synthetase (FAS), ACC and MCD, enzymes 
that regulate Malonyl-CoA levels (147). Hypothalamic Malonyl-CoA level serves as an 
indicator of global energy status and participates in the regulation of feeding behavior. 
CPT1C expression is also enriched in other brain regions implicated in feeding behavior such 
as amygdala, a region involved in emotion, reward and food intake (48, 147) and 
hippocampus, a region important for learning and memory where CPT1C is co-expressed 
with CPT1A (48, 64). 
Cpt1c knock out mice are viable and fertile and display no obvious histological abnormalities 
through life. This suggests that CPT1C is not required for life or neuronal survival (116, 189).  
Cpt1c knock-out in mice of different genetic backgrounds reveal a complex metabolic 
phenotype. Cpt1c knock-out mice ingest less food and have a lower body weight than wild 
type (wt) littermates (116, 176, 189). When fed a high fat diet (HFD) the Cpt1c knock-out 
mice have a markedly increased susceptibility to weight gain although the food intake 
remains lower than in wt mice (116, 176, 189). Consistent with these results, extopic 
expression of CPT1C in hypothalamic feeding centers leads to a significant reduction in 
weight gain in response to a HFD (116, 176, 189) without affecting the food intake. In 
addition these mice also display a severe insulin resistance in response to HFD (116, 176, 
189). Fasting conditions reduce whole body -Oxidation of Cpt1c knock-out mice if 
compared to wt littermates while whole body -Oxidation is equal during ad libitum feeding 
(116, 176, 189).  
The expression of CPT1C in the hypothalamic feeding centers as well as the metabolic 
phenotype observed in the knock-out mouse suggest for a regulatory rather than a metabolic 
role of CPT1C and an involvement of CPT1C in peripheral energy sensing and homeostasis. 
The molecular pathways underlying this phenotype nevertheless need to be further 
investigated. In contrast to the Cpt1c knock-out mouse where no morphological changes have 
been observed, murine embryonic stem cells (ES cells) depleted of CPT1C (Cpt1cgt/gt) display 
significant changes in mitochondrial morphology if compared to Cpt1cwt/gt and Cpt1cwt/wt ES 
cell control. These cells contain swollen mitochondria that display an abnormal internal 
membrane structure and a loss of cristae structure (236). Additionally, these cells exhibit a 
reduction in cell diameter and cell survival due to caspase 3 and 9 activation. Cpt1cgt/gt ES 
cells show an abnormal accumulation of lipid droplets in the cytoplasm and furthermore 
display significant changes in the intracellular lipid profile (236). Loss of Cpt1c function in 
ES cells has been shown to decreased cell survival in response to hypoxia and glucose 
deprivation (236).  
In contrast to the metabolic phenotype observed in Cpt1c knock-out mice, the intracellular 
localization as well as the catalytic activity are controversial in the literature (116, 170, 176). 
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It has been shown that CPT1C like CPT1A and CPT1B is expressed in the mitochondria of 
cultured neurons (48, 116).  
In contrast to this result, a different publication showed that CPT1C expressed in the 
endoplasmatic reticulum in fibroblasts transiently transfected with CPT1C (170). 
Additionally, while different studies failed to show a catalytic activity of CPT1C (116, 176), 
one study showed that CPT1C has carnitine acylcarnitine transferase activity upon 
constitutive expression in neuronal PC-12 cells (170). Constitutive expression of CPT1C in 
PC-12 cells however, fails to increase -Oxidation rates (170). Further studies are necessary 
to solve this controversy and to further elucidate the molecular function of CPT1C in neurons. 
 
1.5.2 CPT1C function in cancer 
 
Very little is known about the role of CPT1 family members in carcinogenesis. Nevertheless, 
the implication of CPT1C in the hypothalamic regulation of peripheral energy expenditure 
(116, 117, 147) and ES cell survival in response to hypoxia and glucose deprivation (236) 
make it a worthwhile target for cancer-related studies.  
It is well established that obesity is a major risk factor for the development of various cancers 
(WHO, 102, 108, 208). Although the cellular and molecular pathways involved in this process 
are poorly understood, the link between obesity and carcinogenesis has been found by several 
studies during the last years (102, 108, 177, 209). 
Activation of metabolic pathways by metabolic stress like hypoxia or missregulation by 
mutations have been shown to contribute to tumor development (WHO), metabolic adaptation 
of tumor cells (86, 102, 218, 220) and metastasis (220, 228). The metabolic adaptation of 
tumor cells is mainly believed to function through changes in glucose metabolism. Recent 
studies nevertheless show that FAs serve as an important energy source in some cancer types. 
Up to now only one study has been submitted that implicates changes in CPT1C expression to 
cancer development (236). The analysis of CPT1C mRNA expression in lung cancer samples 
shows that CPT1C is overexpressed in most of the lung tumor samples. The same study 
showed that CPT1C expression in established cancer cell lines is controlled by pathways that 
have been shown to contribute to carcinogenesis. CPT1C is a direct transcriptional target of 
p53, which is recruited to the CPT1C gene locus in response to glucose deprivation and 
hypoxia. Furthermore, CPT1C mRNA expression is induced by hypoxia and AMPK 
activation upon glucose starvation.  
Consistent with the results obtained with Cpt1c-deficient ES cells (236), CPT1C-depleated 
established cancer cell lines display a reduction of cell growth under hypoxic conditions as 
well as reduced tumor growth in Xenograft assays. Tumor growth was further reduced by 
treatment with the AMPK inhibitor Metformin. While cells depleted from CPT1C display a 
reduction in ATP production, constitutive expression of CPT1C results in significantly 
increased levels of ATP production and FAO. Additional studies are necessary to validate 
these experiments and to elucidate the role of CPT1C in carcinogenesis and the mechanisms 
underlying the phenotypical changes induced by CPT1C depletion or over-expression. 
Elucidating the mechanism by which CPT1C influences the sensitivity to hypoxia may 
provide a novel approach to improve the prognosis of hypoxic and therefore treatment-
resistant cancers.
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Abstract  
Translational control is utilized as a means of regulating gene expression in many species. In 
most cases, posttranscriptional regulatory mechanisms play an important role in stress 
response pathways and can lead to dysfunctional physiology if blocked by mutations. 
CPT1C, the brain-specific member of the CPT1 family, has previously been shown to be 
involved in regulating metabolism in situations of energy surplus. Sequence analysis of the 
CPT1C mRNA revealed that it contains an upstream open reading frame (uORF) in the 5’ 
UTR of its mRNA. Using CPT1C 5’ UTR/luciferase constructs, we investigated the role of 
the uORF in translational regulation. 
The results presented here show that translation from the CPT1C main open reading frame 
(mORF) is repressed by the presence of the uORF, that this repression is relieved in response 
to specific stress stimuli, namely glucose deprivation and palmitate-BSA treatment, and that 
AMPK inhibition can relieve this uORF-dependent repression. The fact that the mORF 
regulation is relieved in response to a specific set of stress stimuli rather than general stress 
response, hints at an involvement of CPT1C in cellular energy-sensing pathways and provides 
further evidence for a role of CPT1C in hypothalamic regulation of energy homeostasis. 
 
Introduction  
The presence of upstream open reading frames (uORF) within mRNA 5´UTR can impact 
levels of translation initiation of the main open reading frame (mORF). Because eukaryotic 
ribosomes generally only initiate once per mRNA (1), the presence of an uORF normally 
inhibits the translation of the mORF and may lead to mRNA decay (2, 3, 4). Although they 
are usually short sequences, uORFs may still play critical roles in modulating physiology. 
Indeed, mutations that introduce new or disrupt existing uORFs have been reported to cause 
human diseases (5, 6, 7, 8).  
Carnitine Palmitoyltransferase 1 (CPT1) C is an isoform of the CPT1 family that is expressed 
specifically in the brain under normal conditions (9). It is well established that CPT1A and 
CPT1B, the other two CPT1 family members, catalyze the initiating step of fatty acid 
degradation through which long chain fatty acidy are transported from the cytoplasm to the 
mitochondrial matrix for -oxidation (10, 11). In this enzymatic reaction, the fatty acyl group 
is transferred from acyl-CoA to carnitine to allow transport into mitochondria. The fact that 
CPT1C is mainly expressed in the CNS (9, 12), a tissue normally not using fatty acids as a 
major energy source, suggests a potentially unique function for CPT1C. Recent publications 
show that CPT1C expression in the brain is mainly restricted to the hypothalamic feeding 
centres, where lipid metabolism is believed to play a key role in regulating peripheral energy 
homeostasis. Results derived from studies using Cpt1c knock out mice implicate CPT1C in 
the regulation of energy homeostasis and the control of food intake (13, 14). Although Cpt1c 
has been shown to be involved in hypothalamic energy sensing, its molecular function, 
regulation and signalling pathways still remain controversial (12, 14, 15, 16). 
Analysis of the mRNA sequences revealed that CPT1C is the only CPT1 member that 
contains an uORF and that the presence of CPT1C uORFs is conserved in several mammalian 
species. Experiments using luciferase reporter constructs transfected into brain-derived cell 
lines reveal that the presence of the uORF inhibits the translation of the downstream mORF. 
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In addition, these experiments showed that the translation inhibition by the uORF is 
derepressed in situations of glucose deprivation and palmitate-BSA treatment. 
 
Material and methods  
 
Computational analysis of the CPT1C mRNA 
RNA secondary structure was calculated with the help of the MFOLD program version 3.2 
from the Michael Zucker homepage (http://mfold.bioinfo.rpi.edu/cgi-bin/rna-form1.cgi). 
Calculations were performed with default settings. 
 
Plasmid construction 
The 5`UTR of the CPT1C transcript was amplified from the cDNA clone (MGC, Invitrogen) 
by PCR under standard conditions using the following primer (restriction sites are underlined) 
fwd 5`-CTC GAG GGA ATC GGG GTT TCT GGG TGA CGG-3`and rev 5`-AAG CTT 
GTC ACG CTG GAG CCC ACG  and cloned into a TA vector (Invitrogen). To create a 
construct lacking a functional start codon in addition to the wt 5´UTR construct, the ATG of 
the uORF was mutated to ACG with the following primers fwd 5`-GGC ATT GGA CAT 
ACG CAA GCG GGA G-3´ and rev 5´-CTC CCG CTT GCG TAT GTC CAA TGC C-3´ 
using a standard side directed mutagenesis PCR. After sequencing, the XhoI/HindIII 
restricted inserts of both constructs were subcloned into the phCMV-Cluc-FSR vector 
(Genlantis). 
 
Preparation of Fatty Acid-BSA complexes 
20% essentially fatty acid free BSA was prepared in 150mM NaCl and sterile filtered. 20mM 
fatty acid was sapoficated and dissolved in 150mM NaCl heated up to 65°C. The free fatty 
acid was complexed to BSA by adding an equal volume 20% BSA to the 65°C fatty acid 
solution and stirred for 10min. The solution was allowed to cool down under stirring and 
sterile filtered before alliquoting. 
 
Cell culture 
The human Glioblastoma cell lines T98G and U87-MG and the SV40 large T-Ag 
immortalized fetal human non-neoplastic astrocytic cell line SV40-FHAS were purchased 
from the American Type Culture Collection (ATCC). 
The cells were maintained in monolayer culture in DMEM containing 4.5g of glucose 
supplemented with 10% FBS, 1% L-Glutamine and 1% Penicillin/Streptomycin. All cells 
were grown in a humidified atmosphere of 5% CO2 at 37°C. 
For hypoxic conditions, the T98G cells were cultured at 37°C with 5% CO2, 94% N2 and 
0.2% O2 in a hypoxic incubator (Scholzen AG). For all fatty acid treatments the supplements 
were added to the normal growth medium. For the starving conditions either DMEM or 
DMEM without glucose supplemented with 1% L-Glutamine and 1% Penecillin/Streptomycin 
with and without 10% FBS was used. 
 
Luciferase assay 
T98G cells were co-transfected with the firefly luciferase constructs and the pRL-SV40 
renilla luciferase vector (Promega) using Lipofectamine 2000 (Invitrogene) and seeded 12h 
prior to treatment with 104 cells in 96 Micro-Assay-Plates (Greiner-bio-one). Relative 
luciferase levels were determined by the ratio of firefly luciferase and renilla luciferase 
activity. The luciferase activities were measured by the Dual-Glo Luciferase System 
(Promega) according to the Dual-Glo Luciferase System manual (Promega) using the Glomax 
96-well luminometer (Promega). All experiments were repeated at least 3 times in triplicates 
and included Mock transfections and transfections with the phCMV-cLuc-FSR vector. 
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Results  
 
Human CPT1C mRNA contains an uORF upstream of the mORF.  
The CPT1C gene consists of 21 exons that give rise to two transcript variants.  Although both 
mRNAs are transcribed from the same gene, both transcript variants differ in lengths and 
exon content. In both transcript variants exon 2 and parts of exon 16, and in transcript variant 
2 also exon 3, are not part of the spliced mRNA. These exons, although not part of the mRNA 
might, however, have a regulatory function for either transcriptional or posttranscriptional 
regulation mechanisms.  
Both mRNAs, however, contain one uORF maintaining the same start codon but stop codons 
derived from exon 3 and exon 4 respectively. The uORF within transcript variant 1 starts at 
bp 97 and has a stop codon at bp 198 resulting in a 34 AA long peptide. The uORF within 
transcript variant 2 on the other hand starts at bp 91 and the corresponding stop codon at bp 
206 resulting in a 37 AA long peptide. Neither of the peptides produced by the uORFs has 
any similarity to known proteins or protein domains. A computational RNA folding 
prediction using MFOLD revealed that although both transcript variants show significantly 
different folding patterns at 37°C, the uORF ATG of both transcript variants are located in 
bubble-like structures while the ATG of the mORF are located in double-strand sections (data 
not shown).  
 
CPT1C is the only CPT1 family member containing an uORF upstream of the mORF. 
CPT1C mRNA sequence analysis revealed that the presence of an uORF is conserved in 
CPT1C mRNAs of different species but not within the CPT1 family of proteins. CPT1C 
mRNA sequences of various species listed on NCBI showed that all mRNAs contain long 5´ 
UTRs harbouring one or several uORFs (Table 1).  The sequences and number of the 
mammalian CPT1C uORFs can vary significantly suggesting that the subsequent peptide(s) 
are not functional. For example, whereas the human CPT1C mRNA contains a single uORF 
out of frame with the mORF, the rat CPT1C mRNA contains three uORF´s that are located 
both in frame as well as out of frame with the mORF.  It should be noted that no paralogs of 
CPT1C have been annotated as such for non-mammalian vertebrates. To determine whether 
the presence of an uORF is also a common feature of the whole CPT1 family, we analyzed 
the mRNA sequences of the other two CPT1 family members, CPT1A and CPT1B. This 
analysis, however, revealed that both mRNAs have short 5´ UTRs containing no similar 
uORFs (Table 1).  Indeed no annotated mammalian CPT1A or CPT1B paralog demonstrated 
an uORF (data not shown).  This conservation suggests the CPT1C uORFs may be functional 
components of the mRNA that can regulate translation of the mORF.  MFOLD analysis of 
CPT1C paralogs indicate that although they do not share common mRNA folding pattern, the 
part that contains the uORF ATG is located in a bubble-like structure similar to human 
CPT1C (Figure 1A). 
 
 
 
 
 
 
 
 
 
 
 
32 
The CPT1C 5’UTR contains a repressing upstream open reading frame that is regulated by 
cellular energy availability and AMPK 
33 
Table 1: uORF distribution and 5´UTR length throughout the CPT1 family 
 
species   5´UTR length no. uORF´s 
human CPT1A 170bp 0 
human CPT1B 84bp 0 
human CPT1C transcript variant 1 281bp 1 
human CPT1C transcript variant 2 206bp 1 
mus musculus cpt1c 194bp 2 
rattus norwegicus cpt1c 199bp 3 
bos taurus cpt1c 225bp 2 
pogo abelii predicted cpt1c 228bp 1 
 
     human            mus musculus         rattus norwegicus  
  
Figure 1: CPT1C uORFs are conserved in evolution and share structural elements. 
Secondary mRNA structure of CPT1C paralogs. Folding was performed using MFOLD with 
default parameters at 37°C. uATG, uORF initiator codon, ATG, mORF initiator codon. 
 
 
Effects of the CPT1C uORF on the translation of the downstream mORF 
Short uORFs can function as regulatory elements on the level of translation. The presence of 
the uORF in both CPT1C transcript variants suggests that both variants can be regulated by 
the same mechanism (Fig. 1A). Because of this similarity between the transcript variants, we 
chose to only use the 5`UTR of CPT1C transcript variant 1 for further experiments.  To 
analyse the uORF function, we cloned the CPT1C 5’UTR upstream of a luciferase reporter 
from a heterologous CMV immediate early promoter.  As a negative control for non-uORF 
activities of the 5’UTR, we also cloned the same sequence where the start codon ATG of the 
uORF was mutated to ACG (Fig. 2A).  Transfection of glioblastoma-derived T98G cells 
demonstrated that the 5´UTR containing the mutated start codon exhibit a 3-fold higher 
luciferase activity than cells transfected with the 5´UTR containing the start codon (Fig. 2B). 
SV40-FHAS and U87-MG cells transfected with the plasmids contained the mutated uORF 
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also had an increase in luciferase activity (2.5- and 2.6-fold, respectively) when compared to 
the wild type (wt) luciferase reporter construct (data not shown). The difference in translation 
efficiency was observed 24h as well as 36h after transfection. These data indicate that the 
presence of the intact uORF of the CPT1C mRNA inhibits the translation of the mORF under 
normal growth conditions.  
 
CPT1C mORF translation is increased in response to glucose deprivation 
Most of the previously examined uORFs have been shown to regulate the translation of the 
mORF in response to the cellular environment.  In order to test whether different metabolic 
stress stimuli influenced CPTIC 5’UTR activity, we treated the T98G, SV40-FHAS and U87-
MG cells transfected with the wt uORF luciferase reporter constructs in altered cellular 
environments. 
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Figure 2: CPT1C 5’UTR induces reporter gene repression. 
 (A) Reporter gene constructs containing the CPT1C 5´UTR cloned in front of a luciferase 
reporter gene with either the endogenous uORF start codon (ATG) or the mutated uORF start 
codon (ACG). (B) Luciferase activities of uORF start (filled bars) and uORF no start (empty 
bars) reporters in T98G cells after transfection and maintenance in normal conditions for 24h 
or 36h. RLU, Relative Luciferase Units.  
 
 
To examine the influence of glucose limitation on the uORF-mediated translational 
repression, the cells were incubated in media lacking glucose and/or FBS.  In T98G cells the 
luciferase activity was increased by 1.5 fold after 12h and by 2-fold after 24h glucose 
deprivation (Fig. 3A) compared to cells grown in normal growth medium. Alone, FBS 
deprivation had no effect on luciferase activity at either time point (Fig. 3A). In the absence of 
glucose, however, FBS deprivation did lead to an increase of 2-fold after 12 and 3-fold after 
24h treatment in T98G cells (Fig. 3A) when compared to cells grown in normal growth 
medium. The change of luciferase activity in SV40-FHAS and U87-MG cells upon treatment 
with the described deprivation conditions were similar to the changes observed in T98G cells 
(data not shown).  To exclude that increased luciferase activity in response to glucose 
deprivation was derived from treatment-induced changes in transcriptional activity, cells 
transfected with the mutated 5’UTR construct were treated in parallel to the cells transfected 
with the wt 5’UTR constructed. In the absence of the intact ATG, we did not see any apparent 
changes in luciferase activity in response to the deprivation media (Fig. 3C), suggesting that 
the derepression by is not transcriptionally regulated but, rather, dependent on the uORF. 
To elucidate at what glucose concentration the CPT1C 5’UTR loses repression from the 
regulation by the CPT1C uORF, we performed a glucose titration on the transfected T98G 
cells.  Because we saw little effect from the absence of FBS, we performed the glucose 
titration in the presence of FBS. The first strong increase in firefly luciferase activity can be 
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observed at the titration step containing 1.125g of glucose with a stepwise increase of activity 
until the highest activity is reached in the medium containing no glucose.  The general trend 
of slow increase in luciferase expression, however, suggests that glucose responsiveness of 
the CPT1C 5’UTR is not tight switch but rather a concentration sensor of glucose or a 
glucose-dependent metabolite.  
To exclude that the CPT1C 5’UTR is derepressed in response to general stress pathway 
activation rather than mediating a specific stress response, the cells were treated with 0.2% O2 
for 12h with or without a 12h reoxigenation period following the hypoxic conditions. None of 
the tested hypoxia or reoxigenation conditions led to changes in reporter activity in T98G 
cells (data not shown). 
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Figure 3: Modulation of CPT1C 5’UTR 
repression by varied growth conditions.  
Relative luciferase activities of T98G cells   
transfected with the wt uORF reporter gene 
construct after (A) glucose and/or serum 
deprivation for 12h or 24h; and with (B) 
titration of glucose concentration in media 
after 12 hours. (C) Relative luciferase 
activities of T98G cells transfected with the 
no start uORF reporter gene construct after 
glucose and/or serum deprivation for 12h or 
24h.  
 
CPT1C uORF regulation is influenced by AMPK 
To test whether the derepression by the CPT1C 5’UTR in response to the cellular 
environment is dependent on the activation of AMPK, the transfected cells were treated with 
chemical AMPK activators and inhibitors. Furthermore, the mTOR inhibitor Rapamycin was 
used investigated an involvement of mTOR in potential uORF regulation. 
T98G cells were treated with the different compounds in combination with two different 
deprivation media. The results presented in Figure 3 revealed that the CPT1C uORF is 
sensitive to glucose but not to FBS deprivation. Glucose deprivation leads to low energy 
levels and high intracellular AMP and thus to the activation of AMPK, which starts a 
signalling cascade that aims to protect the cell from metabolic stress (17).  
Treatment with metformin, an inhibitor of hypothalamic AMPK, with and without glucose 
deprivation led to an increase in luciferase activity in a dose-dependent manner. T98G cells 
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treated with 1mM or 10mM Metformin showed to a 1.2- or 2-fold increase, respectively, in 
reporter activity under glucose deprivation conditions (Fig. 4A) and a 1.6- or 3.6-fold 
increase, respectively, if treated with FBS deprivation (Fig. 4B).  Consistent with AMPK 
positively activating the CPT1C 5’UTR repression mechanism, treatment with the AMPK 
agonist AICAR decreased reporter activity under glucose deprivation conditions but not in 
FBS deprivation conditions (Fig. 4A, B).  
 
Figure 4: CPT1C 5’UTR 
repression is relieved by 
AMPK activation.  
Relative luciferase activity 
in T98G cells transfected 
with uORF start reporter 
construct after maintenance 
in media containing either  
 (A) FBS but no glucose or  
(B) glucose but no FBS in 
the presence of AMPK-
inhibitors metformin or 
Compound C, or in the 
presence of the AMPK-
activator AICAR.   
(C) Relative luciferase 
activity in T98G cells and 
transfected with uORF no 
start reporter construct after  
maintenance in the 
presence of AMPK-
activators metformin or 
Compound C, the AMPK-
inhibitor AICAR, or 
mTOR-inhibitor 
Rapamycin 
 
The AMPK-specific inhibitor, Compound C, also induced a derepression of the 5’UTR 
consistent with that seen for metformin.  Curiously, with this compound, higher derepression 
of the reporter activity was seen in the FBS deprivation than in glucose deprivation 
conditions. The increase in luciferase activity was a 4.9-fold increase in FBS deprivation (Fig. 
4B), if compared to a 1.7-fold increase in cells treated with glucose deprivation (Fig. 4A).  
We suggest that this effect is likely due to different pharmacodynamics of Compound C in the 
presence of serum. Again, similar results were seen with the alternate cell line SV40-FHAS 
(data not shown). Analogous to the results shown in Figure 3C, treatment with the 
pharmacological inhibitors in combination with the deprivation media did not affect the 
luciferase activity in cells transfected with the mutated 5’UTR construct containing no Start 
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codon (Fig.4C). This suggests that AMPK activity is likely to be very important in regulating 
this translational derepression of CPT1C. 
Inhibition of mTOR by the specific inhibitor Rapamycin did not influence the CPT1C uORF 
in neither of the tested cell lines under either of the deprivation conditions (data not shown).  
This suggest that the CPT1C 5’UTR is responsive to energy supply and not responsive stimuli 
that mimics amino acid deprivation. 
 
A 
0
0,5
1
1,5
2
2,5
3
3,5
12h 24h
R
LU
control
100uM Palmitate-BSA
300uM Palmitate-BSA
100uM Oleate-BSA
300uM Oleate-BSA
100uM Octanate-BSA
300uM Octanate-BSA
  
 
B 
 
0
0,5
1
1,5
2
2,5
12h 24h
R
LU
100uM Palmitate-BSA
300uM Palmitate-BSA
100uM Oleate-BSA
300uM Oleate-BSA
100uM Octanate-BSA
300uM Octanate-BSA
       
 
Figure 5: Palmitate relieves CPT1C 5’UTR-mediated translational repression. 
Relative luciferase activity of (A) uORF start and (B) uORF no start reporter constructs after 
transfection into T98G cells upon treatment with stated BSA conjugated fatty acids for 12h or 
24h. RLU, Relative luciferase units, Palmitate-BSA, Palmitic acid conjugated BSA, Oleate-
BSA, Oleic acid conjugated BSA, Octanate-BSA, Octanaic acid-conjugated BSA. 
 
Palmitate-BSA treatment releases the CPT1C mORF from the uORF  
It has been established that CPT1C like the other CPT1 family members binds long-chain 
fatty acids (LCFA), although the enzymatic activity of the CPT1C transferase domain is still 
controversial in the literature (12, 14, 15, 16).  Intracellular accumulation of saturated LCFA, 
for example palmitate, in non-adipose tissue leads to an inhibition of proliferation and 
apoptosis (de Pablo, 1999; Mayer, 2010). In cell culture, treatments with different LCFAs 
induce cells stress, whose consequences vary between cell lines and FA concentrations. 
Palmitic and oleic acid are both LCFA and known substrates of CPT1A and CPT1B, whereas 
CPT1C proteins do not catalyze import of short chain fatty acid, for example oleic acid, into 
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the mitochondria (11, 18). To evaluate the impact of palmitic acid, oleic acid and octanoic 
acid on the regulation of the mORF by the uORF, the transfectants were treated with either 
100µM or 300µM FA-BSA.  In normal glucose conditions, treatment with 100µM Palmitate-
BSA for 12h led to a 1.9-fold increase in luciferase activity in T98G cells (Fig. 5.A) and 2.6-
fold in SV40-FHAS cells (data not shown), if compared to the untreated control.  
Here, the increase in luciferase activity was not maintained over a treatment period of 24h 
possibly due to substrate decomposition. After 12h of treatment, 300µM Palmitate-BSA led to 
a small further increase over 100µM treatment levels. At this concentration, however, a 
further increase (5-fold above normal) could be seen after 24h of treatment.  This is 
equivalent to a 4-fold increase over 100µM Palmitate-BSA treatment (Fig. 5A). Furthermore, 
SV40-FHAS cells exhibited an 8-fold increase over normal conditions after 24h of treatment 
(data not shown).  Treatment with neither oleic or octanioc acid at the tested FA 
concentrations resulted in increased luciferase activity (Fig. 5A). In contrast to the results 
shown in Figure 3 and 4 where none of the treatments did affect the luciferase activity in cells 
transfected with the mutated 5’UTR, treatment with 300µM Palmitate-BSA did lead to a 
significant decrease of luciferase activity, which suggest a decrease of transcription in 
response to the treatment. This decrease was not observed when the cells where treated with 
100µM Palmitate-BSA or one of the other two FA at either concentration (Figure 5B). The 
reduction of transcriptional activity seen in the 300µM Palmitate-BSA treated cells suggests 
that the translational derepression is stronger than indicated by the fold change in the wt 
5’UTR transfected cells (Figure 5A).  These data suggest that there is a concentration sensing 
and a time-dependent sensing mechanism used for derepression of the CPT1C 5’UTR.   
 
Discussion  
The above data suggest that CPT1C can be regulated through an uORF and that this 
regulation can be impacted by cellular energy availability and AMPK activity.   
Although CPT1C has structural similarities to the other CPT1 isoforms and binds malonyl-
CoA, neither its enzymatic activity nor its substrate(s) are established (12, 14, 15, 16).  
Sangiao-Alvarellos et. al recently showed that a reduction of CPT1C mRNA expression does 
not necessarily lead to a reduction of CPT1C protein level. While CPT1C mRNA expression 
was markedly decreased in hypothalamic preparations of Dwarf rats, a growth hormone 
deficient rat strain, the CPT1C protein level was not significantly changed compared to the 
wild type control (19).  
The finding that transcriptional as well as translational mechanisms are used to control 
CPT1C suggests that CPT1C expression needs to be tightly regulated in hypothalamus. This 
observation adds further evidence to our hypothesis that the uORF-dependent regulation of 
CPT1C translation plays an important role in the regulation of CPT1C protein level in vivo. 
Our results indicate that uORF regulation within the 5′UTR maintains low basal CPT1C 
expression during unstressed conditions and is important in the translational induction for 
expression during reduced energy availability. 
Regardless of the unknown function of CPT1C in hypothalamus, the post-transcriptional 
regulation suggests that CPT1C gene expression must rapidly change to perform its role. 
Combined with the fact that the Cpt1c gene-deficient mouse demonstrates a metabolic 
phenotype (12), there is increasing evidence that CPT1C gene expression may be an 
important AMPK effector in regulating satiety. 
Independent of the increasing evidence suggesting that this uORF-dependent translation 
regulation of CPT1C protein expression might play a role in hypothalamic energy sensing, the 
role of CPT1C within the complex hypothalamic signalling network still needs to be 
elucidated.  
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Further biochemical studies will be necessary to elucidate the factors through which AMPK 
activation may control this translational derepression and whether AMPK and BSA-Palmitate 
may be functioning through a common mechanism.  
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Abstract 
Commercially available lentiviral systems are widely used tools for stable gene delivery into 
cell lines and tissues.  Although they have long been understood to cause insertional artefacts, 
they are generally believed to be relatively inert on the physiology of the transduced cell, 
Here, we report that transduction of established human cell lines with lentiviral vectors leads 
to a dramatic increase in the Carnitine Palmitoyl Transferase (CPT1) C expression. We 
further demonstrate that this consequence is likely due to HIV components in these vectors. 
These observations suggest that lentiviral based transduction may induce changes of cell 
metabolism due to CPT1C mRNA upregulation. 
 
Introduction 
Carnitine Palmitoyltransferase 1 (CPT1) C is an isoform of the CPT1 family that is expressed 
mainly in the brain under normal conditions (1). It is well established that CPT1A and 
CPT1B, the other two CPT1 family members, catalyze the initiating step of fatty acid 
degradation through which long chain fatty acids are transported from the cytoplasm to the 
mitochondrial matrix for -oxidation (2). In this enzymatic reaction, the fatty acyl group is 
transferred from acyl-CoA to carnitine to allow transport into mitochondria. The fact that 
CPT1C is mainly expressed in the central nervous system (CNS) (1, 3, 4), a tissue normally 
not using fatty acids a as a major energy source, suggests a potentially unique function for 
CPT1C. Recent publications show that CPT1C expression in the brain is mainly restricted to 
the hypothalamic feeding centers, where lipid metabolism has been shown to play a key role 
in regulating peripheral energy homeostasis. Results derived from studies using CPT1C 
knock-out mice implicate CPT1C in the regulation of energy homeostasis and the control of 
food intake (3, 4, 5).  
The use of lentiviral gene delivery systems enables rapid gain- and loss-of-function analysis 
in cells. These lentiviral gene delivery systems are usually based on the generation of 
pseudotype viruses consisting of 1) the envelope protein from the vesiculo-stomatitis virus 
(VSV) which permits attachment of the pseudotype virus to a broad spectrum of cell types, 2) 
the matrix protein from the human immunodeficiency virus (HIV) type-1, gag-pol, which 
includes HIV’s own enzymes that mediate reverse transcription and integration of the 
encapsidated RNA, and 3) two copies of the gene of interest, i.e. the encapsidated RNA, 
under the control of HIV’s long-terminal repeat (LTR) which contains also the necessary 
packaging signals. The system used for our experiments contains all these genetic information 
on three different vectors resulting in the production of pseudotype viruses which are 
replication incompetent. Once infected, the gene of interest is reverse transcribed and 
subsequently integrated into the host cell genome without any further production of infective 
particles (6). 
Our efforts to generate an in vitro loss-of-function system for CPT1C lead us to the surprising 
finding that CPT1C mRNA was induced by lentivirus.  This observation appears to be 
specific in that neither family members CPT1A nor CPT1B were induced.  
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Material and Methods 
 
Plasmid construction 
The shRNA sequences directed against CPT1C and Lamin A (LMNA) as well as an 
unspecific negative control shRNA (Tab. 1) were designed using the BLOCK-iT RNAi 
designer, synthesized and annealed to the miR RNAi sequence. Four different siRNAs were 
tested for CPT1C and the most efficient sequence was chose for the knock down experiments 
(sequence information upon request). The generated shRNA was inserted into the pcDNA6.2-
GW/EMGFP-miR vector and the sequence was verified by sequencing the corresponding 
fragment. For transduction of the shRNA sequences, the shRNAmir cassette was transferred 
into the pLenti6.2-V5DEST vector which can be packed into viruses produced with the 
ViraPower TM Lentiviral expression system (Invitrogen). The pcDNA6.2-GW/EMGFP-miR 
constructs were used for shRNAmir delivery by transfection. 
 
Table 1: shRNA sequences 
The shRNA sequence forms a hairpin structure that is processed into a mature miRNA (bold) 
while the loop (underlined) and the miRNA* (italics) are degraded.  
 
gene shRNA sequence (5`-`3) 
Scrambled 
control 
AAATGTACTGCGCGTGGAGACGTTTTGGCCACTGACTGACGTCTCCACGCAGTACATTT 
LMNA TGGAAGTCCAGTTCCTCCTTCGTTTTGGCCACTGACTGACGAAGGAGGCTGGACTTCCA 
CPT1C AGAAGATGCGGACCAGGGCCAGTTTTGGCCACTGACTGACTGGCCCTGCCGCATCTTCT 
 
Virus production 
Replication-deficient HIV-based lentivirus for the shRNAmir delivery was produced using 
the ViraPower TM Lentiviral expression system (Invitrogen) according the to manufacturer’s 
instructions.  
 
Cell culture 
The human cell lines T98G, U87-MG, MCF7 and MDA-MB-231 were purchased from the 
American Type Culture Collection (ATCC). The cells were maintained in monolayer culture 
in DMEM supplemented with 10% FBS, 1% L-Glutamine and 1% Penicillin/Streptomycin. 
All cells were grown in a humidified atmosphere of 5% CO2 at 37°C. 
For stable cell line generation cells were either infected with the produced replication-
deficient virus or transfected with cDNA6.2-GW/EMGFP-miR using Lipofectamine 2000 
(Invitrogen) (7) according to the manufacture’s manual or infected with an MOI of 1. Stable 
clones were selected under antibiotic selection with 8µg/ml Blasticidine after 14 days and 
pools of the generated stable clones were used for analysis. 
TZMBL cells, a HELA derived cell line were infected with HIV and served as a positive 
control for HIV infection-related effects.  
 
Quantitative RTPCR Analysis 
Total RNA was extracted from cells with the Trizol Plus Mini-to-Midi RNA extraction kit 
(Invitrogen)  and cDNA was prepared using the Superscript III cells direct cDNA synthesis 
kit (Invitrogen) according to the manufacturer’s manual. qRT PCR was performed using the 
SYBR Green qPCR Super-Mix UDG kit (Invitrogen). GAPDH was used as an internal 
reference. Relative RNA levels were calculated by the Ct method (8). The following 
primers were used: fwd 5’- ATG ACA TCA AGA AGG TGG TG -3’ and rev 5’- CAT ACC 
AGG AAA TGA GCT TG -3’ for GAPDH; fwd 5’- TGG AAC TCA GTG CCC CTG TG -3’ 
and rev: 5’- GCA GGA AAC ACA CCG GTG AG -3’ for CPT1C; fwd: 5’- AGA AAT GTC 
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GCA CGA GCC CAG AC -3’ and rev: 5’- CCA TGG CCC GCA CGA AGT C –3’ for 
CPT1A; fwd: 5’- CTT TGG CCC TGT AGC AGA TGA -3’ and rev: 5’- TGC TCT CTG 
AGC TTG AGA ACT T -3’ for CPT1B. 
 
Results 
 
Up-regulation of CPT1C by lentiviral transduction with shRNAmirs 
We used lentiviral-delivered shRNAmirs directed against CPT1C and LMNA in different 
well-characterized human breast or brain cancer cell lines. A scrambled shRNAmir served as 
control for unspecific effects.  
All cell lines transduced with the pseudotype viruses containing the shRNAmir constructs 
either directed against CPT1C or LMNA revealed an unexpected increase of CPT1C mRNA 
expression as assayed by quantitative RT-PCR. Similarly, there was also an unexpected 
increase in the cell lines transduced with the scrambled shRNA. In particular, transduction of 
T98G and MDA-MB-231 cells with the scrambled control led to an increase in CPT1C 
mRNA level by 473% and 326% respectively (Fig. 1A). Although the cells infected with the 
shRNAmirs directed against CPT1C showed a relatively reduced level of CPT1C mRNA it 
was still induced relative to the parental cell line. 
To exclude that the transduction with the shRNAmir-containing virus was not causing a 
relative reduction of the internal control mRNA, GAPDH, we also examined the normalized 
mRNA expression of CPT1A and CPT1B. Neither CPT1A (Fig. 1B) nor CPT1B (Fig. 1C) 
expression was increased after transduction. 
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Figure 1: CPT1C mRNA level is elevated in response to transduction.  
Cells transduced with lentiviral based vectors containing different shRNAmir constructs. 
Normalized hCPT1C (A), hCPT1A (B), hCPT1B (C) mRNA expression in T98G (empty 
bars) and MDA-MB-231 (filled bars) cells. 
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CPT1C mRNA is not induced by stable transfection 
In order to better understand what factors may be causing this unexpected induction of 
CPT1C, we used the shRNAmir plasmid without lentiviral delivery. In contrast to the cells 
which were successfully transduced with the replication-deficient viruses, cells genetically 
complemented with pcDNA6.2-GW/EMGFP-miR by transfection showed the expected loss 
of mRNA expression (Fig. 2).  
CPT1A and CPT1B mRNA expression in the stable transfectants was used as an indicator for 
transfection-dependent changes in mRNA expression. MDA-MB-231 stable transfectants did 
not show any changes in CPT1A and CPT1B expression in the stable transfectants when 
compared to the untreated control (Fig. 2B, C). While CPT1A mRNA expression in the stable 
T98G transfectants was not changed upon transfection with the unspecific control shRNAmir 
or the LMNA shRNAmir, transfection with CPT1C shRNAmir led to an increase in CPT1A 
mRNA expression (Fig. 2B). CPT1A expression upon CPT1C knock down might be induced 
in order to compensate for the reduction in CPT1C mRNA level. CPT1B expression in 
contrast was reduced in all of the stable transfectants if compared to the untreated control 
independent of the transfected shRNAmir construct (Fig 2C). 
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Figure 2: CPT1C mRNA is not upregulated in response to transfection. 
Transfection of cells with different shRNAmir constructs. Normalized hCPT1C (A), hCPT1A 
(B), hCPT1B (C) mRNA expression in T98G (empty bars) and MDA-MB-231 (filled bars) 
cells. 
 
HIV1 infection induces CPT1C mRNA 
In order to investigate whether HIV1 components of the lentiviral delivery system were 
responsible for CPT1C mRNA induction, we examined the impact of HIV infection on 
CPT1C mRNA. TZMBL cells were either mock infected or infected with HIV and examined 
for CPT1C mRNA expression. The HIV infected cells showed a 466% increase in CPT1C 
mRNA expression when compared to the Mock infected sample (Fig. 3A). As implicated by 
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the infection with the shRNAmir-containing virus, the mRNA expression of CPT1A (Fig. 3B) 
or CPT1B (Fig. 3C) was not affected by HIV infection. 
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Figure 3: CPT1C is upregulated in response to HIV infection. 
Infection of TZMBL cells with HIV. Normalized hCPT1C (A), hCPT1A (B), hCPT1B (C) 
mRNA expression. 
 
Discussion 
Lentiviral systems are commonly used for the transfer of DNA into dividing as well as non-
dividing mammalian cells.  
All available viral systems contain only the parts of the viral genome that are absolutely 
necessary for efficient virus generation, target cell infection and integration of the gene of 
interest. The use of self-inactivating packaging vectors and specific cell lines for virus 
production are commonly used for the production of replication deficient viruses containing 
the gene of interest. Although these systems are well characterized under infection efficiency 
and biosafty criteria, the cellular side effects of those infections are not fully understood yet.  
Independent of all the precautions undertaken during the generation of these lentiviral 
systems, the produced virus might nevertheless be able to change cell signaling upon 
infection. 
The results presented here show that infection of established cancer cell lines with a lentiviral 
system used to transfer shRNAmir constructs results in the upregulation of CPT1C mRNA 
expression. This upregulation was not observed after chemical transfection of the shRNAmir 
constructs. Infection of TZMBL cells with HIV particles displayed an increase in CPT1C 
mRNA expression that was similar to the one observed upon infection with the shRNAmir-
containing virus.  
These results show that the undesired upregulation of CPT1C mRNA observed after viral 
transfer of shRNAmir constructs results from the virus infection and is not a consequence of 
the transferred shRNAmirs. 
It is well established that viral proteins interact with host cell proteins to change cell 
metabolism and signaling, the effect observed in the presented experiments might therefore 
result from changes in cell signaling cascades during the viral infection.  
The unspecific change in CPT1C mRNA level in response to virus infection might lead to 
phenotypic changes in the stable clones that are not induced by the transfer of the gene or 
shRNA of interest and which might lead to misinterpretations in phenotypic characterizations 
of stable knock down clones generated using lentiviral delivery systems. 
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Abstract 
All solid tumors independent of their origin contain areas of low oxygen. Hypoxic cells are 
highly aggressive and metastatic and mostly resistant to therapeutic approaches. Cell invasion 
and metastasis mark the most lethal phase of cancer and account for the majority of cancer 
deaths. Although very little is known about the molecular signaling pathways that trigger 
cancer metastasis, hypoxia is thought to activate signaling pathways that stimulate 
invasiveness of cancer cells.  
The Carnitine Palmitoyltransferase 1c (CPT1C) has recently been identified as a p53-
regulated brain-specific Carnitine Palmitoyltransferase (CPT) 1-family member that is 
upregulated in response to low oxygen availability. The role of CPT1C in brain, a tissue 
mainly utilizing glucose as a primary energy source, is still unsolved. Our previous data 
strongly suggest a role of CPT1C in the regulation of energy sensing and expenditure and 
furthermore implicate CPT1C in carcinogenesis. 
In this study we examined the role of CPT1C in tumorigenesis in established human breast 
and brain cancer cell lines as well as in human pediatric brain tumor samples. The results 
presented here show that CPT1C expression level renders cell proliferation and invasion in 
vivo and in vitro. In addition, CPT1C expression level is regulated by hypoxia and HIF1 
stabilization and correlates with tumor hypoxia in brain tumor samples.  
Understanding of CPT1C function in carcinogenesis might give further insight in how cells 
are protected from hypoxic stress and may present a target through which to sensitize cells to 
hypoxia-induced cell death in cancer treatment. 
 
Introduction 
Metabolic stress, such as hypoxia, induces genetic and epigenetic selection for cancer cells to 
survive the hostile tumor environment. Although metabolic adaptation is prominently linked 
to a dysregulation of glycolysis, use of fatty acid oxidation (FAO) as an energy source has 
also been implicated in this process. 
FAO is regulated at the step of fatty acid import into the mitochondria, which is controlled by 
activity of the CPT1 enzymes. Three CPT1 genes, demonstrating generalized tissue 
specificity, have been identified in mammals. The physiological roles of CPT1A, the 
prominent CPT1 gene in liver, and CPT1B, the prominent CPT1 gene in muscle, are well 
established primarily due to their role in pathogenicity (1). In contrast, the physiological role 
of CPT1C, the isoform primarily expressed in brain tissues, remains elusive.  
The fact that CPT1C is mainly expressed in the CNS (2, 3), a tissue normally not using fatty 
acids as a major energy source, suggests a potentially unique function for CPT1C. Recent 
publications show that CPT1C expression in the brain is mainly restricted to the hypothalamic 
feeding centers, where lipid metabolism is believed to play a key role in regulating peripheral 
energy homeostasis. Results derived from studies using Cpt1c knock-out mice implicate 
CPT1C in the regulation of energy homeostasis and the control of food intake (3, 4). 
Although Cpt1c has been shown to be involved in hypothalamic energy sensing, its molecular 
function, regulation and signaling pathways still remain controversial (3, 4, 5, 6). 
It has been shown that CPT1C mRNA expression is induced by hypoxia. In addition, cancer 
cell lines depleted of CPT1C display reduced cell proliferation and Xenograft tumor growth 
(7). 
Analysis of CPT1C expression in lung cancer samples revealed that CPT1C is overexpressed 
in most of human lung tumor samples, suggesting an involvement of CPT1C in cancer. The 
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role of CPT1C in tumor formation and cancer progression nevertheless needs to be further 
elucidated.  
The ability of tumor cells to invade distant tissue is a critical step in metastasis and the main 
cause of cancer-related death. This process involves the detachment of cells from the primary 
tumor, invasion through the basement membrane, intravasation into the blood stream and 
extravasation from the blood stream at a distant site where cancer cells proliferate and give 
rise to metastases (8, 9, 10, 11). It is well established that normal cells as well as tumors need 
oxygen to generate energy and most of the fundamental processes driving cell proliferation 
and survival. In tumor cells nevertheless, hypoxia is also strongly associated with tumor 
progression and metastasis (12, 13, 14, 15, 16). It has been hypothesized that low oxygen 
tension promotes metastasis by causing the cells to switch to anaerobic metabolism and 
promoting angiogenesis (17). This hypothesis has been strongly supported by studies showing 
that the Hypoxia Inducible Factors (HIFs) play critical roles during tumor cell metastasis by 
regulating energy metabolism, the induction of angiogenesis, cell detachment, invasion, and 
tumor cell seeding (13, 15, 17, 18). Yet, the signaling pathways and molecules involved in the 
hypoxia-dependent induction of tumor cell spreading mostly remain elusive. 
Our study aimed to investigate a possible involvement of CPT1C in tumorigenesis and cancer 
progression as it was suggested by earlier studies (7). Here we show that CPT1C expression 
renders cell proliferation and migration in established brain and breast cancer cell lines. Cells 
depleted of CPT1C show a significant reduction of cell proliferation under hypoxic conditions 
and a reduced migration and invasion potential, while cells constitutively expressing CPT1C 
display a dramatic increase in cell proliferation as well as metastatic potential in vitro and in 
vivo under normal growth conditions. Furthermore, we demonstrate that CPT1C mRNA 
expression is induced by hypoxia and HIF1 stabilization and that CPT1C mRNA expression 
correlates with tumor hypoxia in pediatric brain tumor samples. 
Although very little is known about the function of CPT1C, the fact that CPT1C is mainly 
expressed in the central nervous system (3, 4, 5, 6), a tissue normally not using fatty acids as a 
major energy source, suggests a potentially unique function for CPT1C. Understanding the 
involvement of CPT1C in carcinogenesis might not only be a worthwhile route for the 
treatment of hypoxic tumors, but will also give further insight into the role of CPT1C in 
normal brain tissue. 
 
Material and Methods 
 
Plasmid construction 
The shRNA sequences directed against CPT1C and LMNA as well as an unspecific negative 
control shRNA were designed, synthesized and annealed to the miR RNAi sequence. The 
generated shRNA was inserted into the pcDNA6.2-GW/EMGFP-miR vector and the sequence 
was verified.  
The CPT1C Ultimate ORF clone was purchased from Invitrogen. The ORF was transferred 
from the pENTR221 vector (Invitrogen) to the pcDNA-DEST40 vector for His-tagged or 
pcDNA-DEST47 vector for GFP-tagged protein expression using the LR Clonase reaction 
(Invitrogen) according to the manufacture’s guidelines and the sequence was verified. 
 
Cell culture 
The human cell lines T98G, MCF7 and MDA-MB-231 were purchased from the American 
Type Culture Collection (ATCC). The cells were maintained in monolayer culture in DMEM 
supplemented with 10% FBS, 1% L-Glutamine and 1% Penicillin/Streptomycin. All cells 
were grown in a humidified atmosphere of 5% CO2 at 37°C. 
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For stable cell line generation cells were transfected using Lipofectamine 2000 (Invitrogen) 
according to the manufacturer’s manual. Stable clones were selected for 14 days and single 
clones were established for the subsequent experiments. 
For hypoxic conditions, the cells were incubated at 37°C with 5% CO2, 94% N2 and 0.2% O2 
in a hypoxic incubator (Scholzen AG). 
 
Quantitative RTPCR Analysis 
Total RNA was extracted from cells with the Trizol Plus Mini-to-Midi RNA extraction kit 
(Invitrogen)  and cDNA was prepared using the Superscript III cells direct cDNA synthesis 
kit (Invitrogen) according to the manufacturer’s manual. qRT PCR was performed using the 
SYBR Green qPCR Super-Mix UDG kit (Invitrogen). GAPDH was used as an internal 
reference. Relative RNA levels were calculated by the Ct method (19). The following 
primers were used: fwd 5’- ATG ACA TCA AGA AGG TGG TG -3’ and rev 5’- CAT ACC 
AGG AAA TGA GCT TG -3’ for GAPDH; fwd 5’- TGG AAC TCA GTG CCC CTG TG -3’ 
and rev: 5’- GCA GGA AAC ACA CCG GTG AG -3’ for CPT1C, fwd 5’- TTA AAG GGA 
AGC GGG TCG TTA -3’ and rev 5’- TCC ATT GTC CAA GCA GAA TTT GA -3’ for 
PGK, fwd 5’- GCA CAT AGG AGA GAT GAG CTT C -3’ and rev 5’- CCA CAG GGA 
CGG GAT TTC TTG -3’ for VEGF. 
 
Western Blot 
Total protein was extracted after irradiation and protein concentration was determined. 50µg 
per sample were separated by 8% SDS gel and transferred onto PVDF membrane (GE 
Healthcare). The membranes were blocked with 2% non-fat-dry milk and probed with the 
anti-protein antibodies (Calnexin, Catalase, PCNA [Cell Signalling Technology]; actin 
[SIGMA-Aldrich]; tubulin [SIGMA Aldrich], V5 [SIGMA-Aldrich]). The blots were further 
incubated with horse radish peroxidase (HRP)-labeled antibodies (GE Healthcare) and the 
specific complexes were detected using the ECL Western Blotting Detection Reagents (GE 
Healthcare). 
 
Growth curve analysis 
To assay cell growth, exponentially growing cells were seeded into 6-well plates (NUNC) and 
incubated in a humidified atmosphere at 37°C. Total cell number per well was examined by 
counting every 24h using a Neubauer Improved Hemacytometer. Cells were either grown 
under normal growth conditions (5% Co2) or under hypoxic conditions (5% CO2, 94% N2 and 
0.2% O2) as indicated. 
 
Boyden Chamber Assays 
Cells were resuspended 100μl in DMEM containing 5% FBS and loaded onto the upper 
chamber of a transwell plate with a pore size of 8.0μm Polycarbonate Membrane (Costar). 
600μl conditioned DMEM containing 10% FBS was placed in the lower well, and cells were 
incubated at 37°C in a 5% CO2-supplied incubator for 16 h. For invasion assays, the 
Polycarbonate Membrane was overlaid with 50μl Matrigel Matrix (Basement Membrane) 
(BD) diluted 1:20 in DMEM. To analyze the migration, cells that had migrated to the lower 
surface of the membrane were stained with 0.09% crystal violet and counted under bright-
field microscopy. In each experiment, the numbers of stained cells in three independent image 
fields of the same size were averaged and indicated as relative migration. All migration and 
invasion experiments were done in triplicates and repeated at least 2 times. 
 
Xenograft Assay 
MDA-MB-231 cells (5×106) were injected subcutaneously into BALB/c-nude mice 
(CAnN.Cg-Foxn1<nu>/Crl) (Charles River Laboratories). Tumor growth was assayed in 6 
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mice per group. Tumor size was measured every two days. Tumor volume was calculated 
according to the formula, width2 × length × 0.5. 
 
In vivo metastasis Assay 
The MDA-MB-231 CPT1C gain-of-function clones that were used in the Xenograft assays 
were transfected with the SV40-pGL4.26 luciferase vector for in vivo imaging. Stable clones 
expressing CPT1C and Luciferase as well as the appropriate control clones were injected into 
the tail vein of BALB/c-nude mice (CAnN.Cg-Foxn1<nu>/Crl) (Charles River Laboratories) 
with 106 cell per mouse. A stock solution of D-Luciferin19 (Calliper Life Sciences) at 15 
mg/ml was prepared according to the manufacturer’s instructions. 10 μl/g of body weight 
were injected intraperitoneally (IP) 10-15 minutes before imaging with the IVIS Imaging 
System 200 Series (Calliper Life Sciences). Mice were anesthetized with 5% isofluorane in an 
anaesthetization chamber, reducing to 3% isofluorane as soon as excitation phase passed. The 
mice were fully anesthetized and then transferred from the chamber to the nose cones attached 
to the manifold in the imaging chamber and isofluorane supply was reduced to 2%. Camera 
settings were adjusted and series of five images were taken first from the breast of the mouse 
and second series of five images from the back. Pictures were taken every third day over a 30 
day experimental period. Organs were extracted at the end of the experiment and fixed with 
formalin. Paraffin-embedded sections were stained for hematoxylin and eosin (H&E staining). 
 
Electron Microscopy 
MCF7 stable transfectants were seeded on glass cover slips, grown until confluency in a 
humidified atmosphere of 5% CO2 at 37°C over night and fixed in 2,5% glutaraldehyde for 
30min. Fix was replaced with 2% OsO4 for 30min, and the culture was rinsed and then stained 
with uranyl acetate for over night. Samples were dehydrated in an ethanol series, infiltrated 
with Epon, and polymerized. The embedded cells were cut from the cover slip and sectioned 
for image production. 
 
Statistical analysis 
All data are presented as means  standard deviation (SD). The data was analyzed using the 
statistical program SPSS version 16.0 (SPSS Inc.). Differences among the groups were 
compared by one-way analysis in combination with post hoc Scheffe test. Two-tailed values 
of p0.05 were considered significant. 
 
Results 
 
CPT1C mRNA expression is induced by tumor hypoxia in a HIF1- dependent manner 
It has been demonstrated earlier that CPT1C mRNA expression is upregulated in response to 
hypoxia (7).  
CPT1C expression in established brain cancer cell lines was examined under normoxic and 
hypoxic conditions to investigate if hypoxia regulates CPT1C expression. T98G cells treated 
with hypoxia over 12h showed a significant 2 fold upregulation in CPT1C mRNA expression 
(Fig. 1A). The hypoxia target genes VEGF and PGK mRNA expression were used as controls 
(Fig. 1A). HIF1 is the major transcription factor for the induction of gene expression in 
response to hypoxia. To investigate whether HIF1 is also responsible for the transcriptional 
induction of CPT1C expression we examined the mRNA expression in response to DMOG 
treatment. Treatment with the chemical compound DMOG, a specific cell permeable HIF-α 
prolyl hydroxylase inhibitor, results in the stabilization of HIF under normoxic conditions 
and thus induction of HIF1-dependent target genes. T98G cells treated with 1mM DMOG for 
12h displayed a 1.3 fold induction in CPT1C expression (Fig. 1B). The HIF1 target genes 
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VEGF and PGK served as controls for HIF1-dependent induction and were upregulated 
expectantly in response to DMOG treatment. 
Tumor hypoxia is a critical factor in tumor progression because of the induced epigenetic 
changes which result in the selection of hypoxia-resistant aggressive tumor cells (12, 15, 17). 
In order to investigate whether CPT1C expression correlates with tumor hypoxia in vivo, 
CPT1C and PGK mRNA expression were examined in 54 pediatric brain tumor samples of 
different WHO grades (Fig. 1C). Statistical analysis of the results obtained showed a 
significant correlation between PGK mRNA expression which served as a marker for tumor 
hypoxia and CPT1C mRNA expression (p=0.013) 
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Figure 1: CPT1C expression is induced under hypoxic conditions 
qRTPCR analysis of T98G cells treated for 12h with (A) 0.2% O2 and (B) 1mM DOMOG for 
12h. Relative mRNA expression of CPT1C (empty bars), VEGF (striped bars) and PGK 
(filled bars) normalized to GAPDH. ** p 0.001 (C) qRTPCR analysis of pediatric brain 
tumor samples. Relative expression of CPT1C and PGK normalized to GAPDH.  
 
Constitutive expression of CPT1C leads to increased proliferation in vitro and in vivo 
As shown previously, CPT1C is upregulated in lung tumor samples if compared to the 
matched control (7).  
In order to examine the role of CPT1C in tumorigenesis (Fig. 1C), we generated CPT1C gain-
of-function in different established cancer cell lines. CPT1C expression was examined by 
qRTPCR (data not shown) and Western Blot (Fig 2A), were V5-Tag was used for detection.  
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Growth curve analysis of T98G stable CPT1C gain-of-function transfectants displayed 
significantly reduced doubling times if compared to the control stable transfectants (Fig. 2B). 
Similar results were observed in MCF7 stable transfectants (data not shown). In contrast to 
the results obtained with T98G and MCF7 stable transfectants, MDA-MB-231 stable CPT1C 
gain-of-function transfectants showed no reduction in doubling time in the growth curve 
analysis (data not shown). But if injected subcutaneously into nude mice the stable 
transfectants showed a significant increase in tumor growth when compared to the vector 
control (Fig. 2C).  
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Figure 2: CPT1C gain-of-function induces cell proliferation and tumor growth 
(A) Western Blot of T98G stable gain-of-function transfectants for H5-tagged transgene 
expression. (B) Growth curve analysis of T98G cells constitutively expressing CPT1C. (C) 
Xenograft tumor growth assay of MDA-MB-231 gain-of-function stable transfectants. 
 
CPT1C loss-of-function inhibits cell proliferation in response to hypoxia 
CPT1C loss-of-function studies in established cancer cell lines showed that depletion of 
CPT1C results in reduced cell proliferation in response to hypoxia and Xenograft tumor 
growth (7). 
To further investigate the phenotypic changes induced by CPT1C depletion, we generated 
CPT1C loss-of-function clones using four different shRNA sequences in T98G and MDA-
MB-231 cells. CPT1C mRNA expression was examined by qRTPCR (Fig. 3A, data not 
shown) and the two clones with the strongest knockdown of CPT1C were used for subsequent 
analysis. Cell proliferation of these CPT1C loss-of-function transfectants was examined under 
normoxic and hypoxic conditions. CPT1C loss-of-function T98G clones showed a significant 
reduction in cell proliferation under hypoxic conditions if compared to the scrambled control 
clones (Fig. 3B). No reduction of cell proliferation was observed under normoxic conditions 
(data not shown). Similar results were obtained with the MDA-MB-231 stable CPT1C loss-
of-function stable transfectants (data not shown). 
 
 
 
 
 
CPT1C: A Putative Regulator of Tumor Growth and Migration 
A 
0
1
2
3
4
5
6
7
8
untreated unspecific
control
hCPT1C hCPT1C 2 hCPT1C 3 hCPT1C 4n
or
m
al
iz
ed
 h
C
PT
1C
 e
xp
re
ss
io
n 
(A
rb
ita
ry
 u
ni
ts
)
 
B 
0
200
400
600
800
1000
1200
0h 24h 48h 72h 96h 120h 144h
ce
ll 
gr
ow
th
(th
ou
sa
nd
s)
control
hCPT1C
 
 
Figure 3: CPT1C loss-of-function reduces cell growth under hypoxic conditions 
(A) qRTPCR analysis of CPT1C expression normalized to GAPDH of T98G stable 
shRNAmir transfectants. (B) Growth curve analysis of T98G stable transfectants (control 
[triangles], CPT1C [squares] under hypoxic conditions. 
 
CPT1C expression renders cancer cell migration and invasion in vitro 
Intratumoral hypoxia correlates with poor clinical outcome in most solid tumors (12, 17). 
Hypoxic stress is a strong driving force during tumor progression and enhanced metastases 
formation by regulating energy metabolism (12, 15, 17). HIF1 signaling is thought to activate 
signaling pathways that stimulate invasiveness of cancer (13, 16). The molecular pathways 
involved, however, are not well understood (14, 15, 18). Our results showing regulation of 
CPT1C expression by hypoxia in a HIF-dependent manner as well as the proliferation 
phenotype prompted us to investigate a possible involvement of CPT1C in cancer cell 
migration and invasion. 
The migration potential of the CPT1C gain- and loss-of-function cell lines was examined 
using Boyden chamber assays. All CPT1C gain-of-function stable transfectants, independent 
of the parental cell line and the expression level of CPT1C, showed a dramatic and highly 
significant increase in cell migration (Fig. 4A, data not shown) if compared to the stable 
control transfectants. CPT1C gain-of-function in T98G cells displayed a 3.5 fold increase in 
cell migration under normoxic conditions if compared to the control (Fig. 4A). Similarly 
increased cell migration potentials were found in all tested CPT1C stable transfectants (data 
not shown).  
T98G stable loss-of-function cells on the other hand, showed a reduction of cell migration. In 
contrast to the hypoxia-dependent reduction in cell proliferation in response to CPT1C 
depletion, cell migration was reduced under both hypoxic and normoxic conditions. If 
compared to the control, T98G cells depleted of CPT1C showed a 1.7 fold reduction under 
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normoxic and 2.3 fold reduction under hypoxic conditions (Fig. 4B). Consistent with the 
results obtained with the gain-of-function stable transfectants, the MDA-MB-231 stable 
CPT1C loss-of-function transfectants showed a similar reduction in cell migration (data not 
shown). 
Cell migration examined by Boyden chamber assays, is a potent indicator for the metastatic 
potential of tumor cells. Migration, however, is only one part of the metastatic process. To 
allow migration within the tissue, cancer cells need to digest the extracellular matrix in order 
to migrate towards the blood vessels.  
Consistent with the results shown for cell migration, CPT1C expression also influences the 
cell invasion potential. T98G cell constitutively expressing CPT1C show a 7.1 fold increase 
in cell invasion (Fig. 4C) while CPT1C depletion decreases cell invasion by 2.3 fold under 
hypoxic and 3.6 fold under normoxic conditions (Fig. 4D). The same phenotype was also 
observed in all other cell lines tested (data not shown). 
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Figure 4: Cell migration and invasion potential is influenced by CPT1C expression 
Boyden chamber migration assays using T98G (A) CPT1C gain-of-function and (B) loss-of-
function cells. Boyden chamber invasion assays of T98G (C) CPT1C gain-of-function and 
(D) loss-of-function cells. Cell migration and invasion was examined under normoxic (filled 
bars) and hypoxic (empty bars) conditions. ** p 0.001 
 
CPT1C expression renders cell invasion in vivo 
While it is unclear how CPT1C may increase cell motility, the correlation between enhanced 
hypoxia tolerance and metastasis in the clinical disease (17) makes this a potentially 
worthwhile avenue for further investigations. 
To examine whether the migratory phenotype observed in vitro is also observed in vivo we 
performed in vivo invasion assays. The MDA-MB-231 stable CPT1C gain-of-function 
** 
** 
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transfectants previously used in the in vitro assays were co-transfected with a constitutive 
firefly luciferase vector and injected into nude mice for the Xenograft migration assays. The 
chemiluminiscent signal detected after luciferin injection is used as a surrogate to estimate 
tumor growth. 
One day after tail vein injection of the stable transfectants, we observed a strong signal in the 
lungs of all mice independent of the injected stable clone. Although this signal subsided until 
day 10, the signal derived from the lung significantly increased over the course of the 
experiment in the control mice (Fig. 5A). In the mice injected with the CPT1C stable 
transfectants in contrast, the signal subsided until day 15 and only showed a slight increase 
over the course of the experiment (Fig. 5A). No further signals above background derived 
from other organs than the lung were observed over the course of the experiment (Fig. 5A). 
Because of the rapid lung invasion observed in the control mice we had to sacrifice the mice.  
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Figure 5: CPT1C gain-of-function increases migration in vivo 
Chemiluminescence optical tracking of the metastatic progression of MDA-MB-231 stable 
CPT1C transfectants. (A) Evaluation of chemiluminescence signals in the breast of mice 
injected with either stable control transfectants (triangles) (n=2) or stable CPT1C transfectants 
(squares) (n=2). (B) Histological confirmation of metastatic lesions formed by the MDA-MB-
231 stable CPT1C transfectants injected s.c.. Metastatic lesions were identified by H&E 
staining. (preliminary results) 
 
To confirm the results derived with the IVIS Imaging System, all organs were extracted and 
examined for metastatic lesions. Macroscopic examination revealed metastatic lesions of the 
lung in both the CPT1C gain-of-function and control mice, although the tumor invasion was 
more advanced in the mice injected with the vector control cells (Fig. 5B). No further lesions 
were observed during examination of brain, liver, heart, kidney and intestine of the control 
mice. Examination of the intestine of the CPT1C gain-of-function cells on the other hand 
showed an enlargement of the lymphatic plaques on the intestine (Fig. 5B). 
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H&E staining of the lung sections confirmed the metastatic invasion observed during animal 
imaging and macroscopic examination. As expected, the mice injected with the control vector 
clones displayed enhanced metastatic invasion of the lung if compared to the mice injected 
with the CPT1C gain-of-function clones and a nearly complete loss of normal lung tissue. 
None of the other organs extracted from the mice injected with either the control vector clones 
or the CPT1C gain-of-function clones displayed any metastatic lesion in the examined 
sections. Because only parts of the organs were examined, metastatic lesions might 
nevertheless be present in the unexamined parts. (preliminary data) 
 
Constitutive CPT1C expression results in increased tubulin expression 
It is well established that the cytoskeleton is the intracellular machinery responsible for 
changes in cell morphology and motility (20). Migration is driven by a continuous cycle of 
actin and tubulin polymerization and depolymerization (20, 21, 22). Cell migration induced 
by changes in the cytoskeleton can not only be induced by mutation of -tubulin leading to 
polymerization and acetylation (20, 21), but also by up regulation of tubulin expression (23, 
24, 25). 
Although all of the generated CPT1C gain-of-function clones independent of the parental cell 
line displayed an increase in cell migration and invasion potential, we decided to use the 
MCF7 stable CPT1C transfectants and the corresponding control stable transfectants for the 
examination of the cytoskeleton. These clones had the highest CPT1C mRNA expression.  
As suggested by the migration and invasion assays, the analysis of the images produced by 
electron microscopy revealed an increase in cytoskeleton stacks in cells expressing CPT1C 
which was not observed in cells transfected with the control vector (Fig. 6B). The 
cytoskeleton stacks were found in all cells examined and evenly distributed over the cells. 
To validate the results obtained from the electron microscopy, we examined total tubulin 
expression by Western Blot analysis. As expected, the CPT1C stable transfectants showed a 
higher expression of tubulin if compared to the stable control transfectants (Fig. 6C). To 
exclude that the difference in tubulin expression was derived from a loading artifacts, total 
protein concentration was determined before loading and calnexin (Fig. 6C) among several 
other cellular proteins (data not shown) were used as loading control. 
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Figure 6: CPT1C gain-of-function renders cell morphology 
Electron microscope image of MCF7 stable transfectants with a 11500x magnification. Cells 
were examined for (A) inclusion bodies and (B) cytoskeleton. (C) Detection of calnexin and 
-tubulin by Western Blot analysis of MCF7 cells stably transfected with CPT1C or the 
control vector. 
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Constitutive CPT1C expression results in the formation of intracellular vesicles 
It has been published earlier that murine CPT1C knock out ES cells display morphological 
changes if examined by electron microscopy (26). These cells show a strong mitochondrial 
phenotype with enlarged mitochondria and a loss of cristae structure. Furthermore, these cells 
contain big lipid droplets. 
In order to examine whether CPT1C loss- or gain-of-function in human cell lines will also 
affect cell morphology, we examined our stable transfectants by electron microscopy. In 
contrast to the results observed in the CPT1C knock-out ES cells, analysis of the T98G stable 
knock-down clones displayed no changes in cell morphology if compared to the scrambled 
control (data not shown). This might be due to the fact that our knock-down system only 
reduces CPT1C mRNA expression and that the remaining CPT1C protein is enough to 
maintain mitochondrial morphology.  
MCF7 gain-of-function of CPT1C on the other hand showed an accumulation of intracellular 
vesicles that was not observed in the control cells (Fig. 6A). In order to determine the nature 
of these vesicles we examined the protein expression of several organelle markers by Western 
blot. None of the tested organelle markers was significantly increased in the gain-of-function 
cells if compared to the control cells (data not shown). Although the nature of the vesicles 
remains elusive they might serve as storage vesicles for over-expressed CPT1C protein. 
Further studies are necessary to elucidate the nature and function of these vesicles. 
 
Discussion 
It has been published previously that constitutive expression of CPT1C in cancer cell lines 
leads to increased FAO and ATP production while depletion of CPT1C has the reverse effect 
(7). Mouse studies show that CPT1C depletion results in a reduced body weight on a normal 
diet, but when fed a diet that is rich in fats, these mice demonstrate an increase in relative 
body weight concurrent with a reduction in both food intake and insulin resistance (3, 5). 
Nevertheless, the transferase activity and the substrate of CPT1C are still controversial in the 
literature (3, 4, 6). Previous results also showed that CPT1C expression is induced in lung 
tumors if compared to matched control tissue (7).  
The results presented here show that depletion of CPT1C in cancer cell lines reduces cell 
proliferation under hypoxic conditions. Under normoxic conditions however, cell 
proliferation is not impacted by CPT1C depletion. Constitutive expression of CPT1C on the 
other hand results in reduced doubling times under normoxic conditions. Furthermore, 
CPT1C expression affects cell migration and invasion. CPT1C depletion resulted in cell 
migration potential in in vitro migration and invasion assays while constitutive expression of 
CPT1C had the opposite effect. In Xenograft metastasis assays in contrast, we could not 
detect an increase in metastasis formation in the mice injected with cells constitutively 
expressing CPT1C if compared to the control mice. The control mice showed a dramatic 
invasion of the lung tissues that forced us to sacrifice all mice. The lower amount of lung 
infiltration observed in the mice injected with cancer cells expressing CPT1C might result 
from an increased migration potential that allowed the CPT1C stable transfectants to leave the 
lung and invade other organs. Our experiments however were not able to give further insight 
in this effect, due to of the rapid lung invasion observed in the control mice that forced us to 
stop the experiment at an early time point. The induction of cell motility however represents 
only one aspect of tumor cell metastasis. Tumor cells that leave the primary tumor have to 
adapt to the blood flow and after the invasion of the distant tissue need to survive the new 
microenvironment. Our CPT1C gain-of-function stable transfectants might either not be able 
to overcome these restrictions or the survival time was too short to result in the formation of 
visible micrometastasis in the mice. 
It is well established that tumor hypoxia induces an epigenetic selection for cancer cells that 
survive in the hostile tumor environment (12, 16, 18). Emerging evidence suggests that the 
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effect of hypoxia is partially controlled by HIF-mediated activation of pathways that enable 
tumor cells to survive or escape their oxygen-deficient environment. HIF promotes the 
selection and expansion of more aggressive clones of cancer cells by transcriptionally 
activating key regulators of metastasis (13, 14, 15) and therefore is believed to be the driving 
force of cancer metastasis (12, 14, 15, 16).  
CPT1C expression is induced by hypoxic conditions and HIF1 stabilization. Additionally, 
CPT1C expression correlates with PGK, a marker of tumor hypoxia in pediatric brain tumors. 
Elevated CPT1C expression levels in cancer cells might therefore result in the activation of 
hypoxia-induced signaling pathways under normoxic conditions and thereby result in the 
observed phenotypes. The signaling pathways involved in the change of cell proliferation and 
migration however are not established yet. Further studies are necessary to elucidate the 
pathways induced by CPT1C in response to hypoxia and to understand the consequences of 
elevated CPT1C expression levels in human tumors. 
Tumor hypoxia is a major therapeutic concern because it reduces the effectiveness of radio- 
and chemotherapy and promotes metastasis. While therapeutic strategies that capitalize on 
chronic hypoxia sensitivity are available, no cellular targets have yet been characterized that 
induce cellular sensitivity to hypoxia. Understanding how CPT1C expression influences 
cancer cells might give new insight for the prediction of therapy efficiency and furthermore 
suggest new therapeutic approaches for the therapy of otherwise treatment-resistant tumors. 
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CPT1C is the brain specific isoform of the CPT1 family. The CPT1 family of proteins has 
been shown to represent the limiting step of -Oxidation by regulating the entry of LCFAs 
into the mitochondria. The fact that CPT1C is highly expressed in brain regions involved in 
the regulation of peripheral energy expenditure (48, 64, 116, 176, 189) suggests a potentially 
unique function for CPT1C. 
CPT1C expression is found in neurons throughout the entire brain but shows the highest level 
in neural feeding centers within the hypothalamus. CPT1C expression is also enriched in 
amygdala and hippocampus, brain regions that are involved in food intake, reward and 
memory (147). Although the anatomical localization of CPT1C has been established by 
different studies, the subcellular localization is still controversial in the literature. Different 
studies have localized CPT1C to either the mitochondria or the endoplasmatic reticulum. Both 
organelles have been shown to be involved in the oxidation of FA. While the endoplasmatic 
reticulum is only involved in the oxidation of very LCFAs, the mitochondrial -oxidation is 
used to degrade long- as well as short-chain FAs.  
Cpt1c knock-out mice independent of the genetic background are viable and fertile and in a 
complex metabolic phenotype. These mice ingest less food and have a lower body weight 
than wild type (wt) littermates (116, 176, 189). When fed a high fat diet the Cpt1c knock-out 
mice have a markedly increased susceptibility to weight gain which can be reversed by the 
extopic expression of CPT1C in hypothalamic feeding centers (116, 176, 189). Additionally, 
Cpt1c knock-out mice display a severe insulin resistance in response to high fat diet (116, 
176, 189). Furthermore, fasting conditions reduce whole body -Oxidation of Cpt1c knock-
out mice if compared to wt littermates (116, 176, 189).  
The expression of CPT1C in the hypothalamic feeding centers and the metabolic phenotype 
observed in the knock-out mouse suggest for a regulatory rather than a metabolic role of 
CPT1C.  
Hypothalamic feeding centers contain nutrient-sensitive neurons which have been shown to 
regulate the desire for food intake and satiety (29, 49, 52, 63, 82, 93, 107, 108, 117, 165) in 
response to specific stimuli. This requires the presence of molecular sensors that detect 
changes in whole body energy expenditure and trigger adaptive responses. Hypothalamic 
AMPK activity is regulated in response to cellular energy level, circulating hormones and 
nutritional cues (29, 44, 52, 63, 93, 117, 165, 224) and is used to sense changes in the whole 
body nutrition status. The modulation of AMPK activity in response to these factors initiates 
signaling pathways leading to changes in feeding behavior (140, 165). The molecular 
mechanism(s) by which hypothalamic AMPK regulates the desire for food intake however are 
still poorly understood. Plasma FA levels are detected by specialized hypothalamic neurons 
which integrate this information in the regulation of feeding behavior. 
A database search on NCBI revealed that the human CPT1C genes gives rise to two transcript 
variants that differ in length and exon content. The existence of these two transcript variants 
might explain the contradictory results obtained by different studies concerning the 
intracellular localization and transferase activity (48, 116, 170). It is well possible that these 
isoforms differ in the subcelluar localization and affinity towards their substrate palmitate and 
serve as regulators of different downstream pathways. Further studies which aim to 
understand the expression profile of the transcript variants might solve the controversy about 
CPT1C localization and function. 
Both mRNAs contain a conserved uORF upstream of the CPT1C-coding mORF. CPT1C 
mRNA sequence analysis revealed that the presence of an uORF is conserved in CPT1C 
mRNAs of different species but not within the CPT1 family of proteins. Because eukaryotic 
ribosomes generally only initiate once per mRNA (38, 158, 182), the presence of an uORF 
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normally inhibits the translation of the mORF and may lead to mRNA decay (3, 8, 35, 37, 
152, 166). 
Using an in vitro luciferase reporter assay we showed that the translation of the downstream 
mORF is indeed repressed by the presence of the uORF. In response to glucose deprivation 
the mORF was released from the translational repression resulting in an enhanced expression 
of the reporter gene. This translational derepression of the mORF was not observed in 
response to serum starvation. Because AMPK has been shown to change gene expression in 
response to changes in energy availability, we also investigated the impact of AMPK activity 
on the translational repression of CPT1C by the uORF. AMPK inhibition by pharmacological 
compounds such as Metformin and Compound C leads to the derepression of the mORF 
independent of glucose availability, while treatment with the AMPK agonist AICAR results 
in repression of the mORF even during glucose starvation. In addition, the mORF is also 
derepressed in response to Palmitate-BSA feeding. Treatment with Oleate-BSA or Octanate-
BSA however did not result in derepression of the mORF. This suggests that the uORF 
regulates the mORF expression in response to a specific set of stimuli rather than mediating a 
general stress response. Surprisingly, treatment with the mTOR inhibitor Rapamycin did not 
affect the uORF mediated repression of the mORF. The specificity of the AMPK and mTOR 
inhibitors and the AMPK agonist AICAR was established by earlier studies (44, 52, 82, 93, 
107, 131, 146). 
Overall, these results suggest that CPT1C translation is regulated by the presence of the uORF 
and that this regulation is impacted by cellular energy availability and AMPK activity. 
Combined with the fact that CPT1C is expressed in neurons of hypothalamic nuclei (48, 147) 
and that the Cpt1c gene-deficient mouse demonstrates a metabolic phenotype (116, 176, 189), 
these results support the evidence that CPT1C gene expression may be an important AMPK 
effector in regulating satiety. The detailed mechanism through which CPT1C may regulate 
peripheral energy sensing however is still unclear.  
The posttranscriptional regulation of CPT1C expression might be used to regulate the 
activation of downstream signaling pathways in response to energy availability. The 
membrane localization provides the possibility that changes in CPT1C expression impact ion 
channel functions, which are critical in neuronal signaling. Regardless, the post-
transcriptional regulation suggests that CPT1C gene expression must rapidly change to 
perform its role. 
It has been previously shown that AMPK can inhibit translation by mTOR (222). Our finding 
that Rapamycin does not induce derepression suggests that AMPK is functioning via a 
different and novel mechanism. Further biochemical studies will be necessary to elucidate the 
factors through which AMPK activation may control this translational derepression. It is also 
unclear whether AMPK and Palmitate-BSA may be functioning through a common 
mechanism. The previous finding that Palmitate may regulate hypothalamic signaling of 
satiety through inhibition of insulin signaling (25) may be an important clue to further 
elucidate the specific effectors between cellular energy availability and CPT1C 5'UTR 
derepression. Further studies are necessary to examine the importance of this regulatory 
mechanism in the hypothalamic regulation of satiety under physiological conditions. 
In additions to its role in normal brain, the p53-target CPT1C has also been hypothesized to 
play a role in cancer. The involvement of CPT1C in the hypothalamic regulation of energy 
sensing and expenditure combined with the finding that CPT1C is upregulated in lung tumor 
samples strongly suggest for an involvement of CPT1C in cancer development. 
Obesity, virus infections and genetic predisposition are established to be important factors in 
the development of cancers (WHO). Though the means by which obesity influences cancer 
development and progression are not fully understood. 
Initially we attempted to generate stable CPT1C loss-of-function clones in various established 
brain- and breast cancer cell lines using a HIV-based lentiviral system. The use of lentiviral 
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systems for the transfer of microRNA-adapted shRNAs (shRNAmirs) allows the rapid and 
efficient generation of stable loss-of-function clones in cell lines. All cell lines transduced 
with the pseudotype virus containing a control shRNAmir or shRNAmirs directed against 
CPT1C or LMNA revealed a dramatic increase in CPT1C expression that was not observed 
after chemical transfection of the same shRNAmirs. A similar upregulation was observed in 
cells infected with HIV-1. Neither of the other CPT1 family members was induced upon 
transduction with the pseudotype virus or infection with HIV-1. These results show that HIV 
infection specifically upregulates CPT1C mRNA expression through a yet unknown pathway. 
The viral components of the lentiviral system might activate pathways that are also induced 
during the virus infection-induced metabolic remodeling. Interestingly, HIV patients have 
been shown to commonly suffer from wasting diseases that are still poorly understood (168, 
188). Induction of CPT1C expression in response to virus infection might be used to achieve 
the observed metabolic changes in order to allow the efficient production of new virus. 
Further studies are necessary to establish the molecular mechanism by which HIV infection 
activates CPT1C expression and to investigate if upregulation of CPT1C expression is 
involved in the manifestation of the metabolic symptoms in HIV-infected patients. 
It has been shown earlier that CPT1C expression is induced by hypoxia which is supported by 
our data (236). Our results furthermore show that CPT1C expression is upregulated in 
response to HIF-1 stabilization. Treatment of different established brain cancer cell lines with 
the chemical compound DMOG, a competitive inhibitor of HIF-PH that acts to stabilize HIF-
1α expression at normal oxygen tensions, results in the induction of CPT1C mRNA 
expression. Additionally, CPT1C mRNA expression correlates with the mRNA expression of 
the HIF-1 target gene PGK in pediatric brain tumor samples. HIF target genes have been 
shown to regulate a number of cellular pathways such as metabolic adaptation, proliferation 
and metastasis.  
To elucidate the role of CPT1C in cancer progression we examined the consequences of 
CPT1C gain-of-function and loss-of-function in human breast and brain cancer cell lines. An 
earlier study showed that CPT1C depletion results in decreased proliferation rates if the cells 
are exposed to hypoxia (236). This phenotype was also observed in our stable transfectants. 
CPT1C depletion in brain and breast cancer cell lines displayed no proliferative phenotype 
under normoxic conditions. If the cells were treated with hypoxia, CPT1C stable loss-of-
function transfectants revealed a significant decrease of cell proliferation.  
Our results furthermore showed that CPT1C gain-of-function leads to a significant increase in 
cell proliferation. Interestingly, this induction of cell proliferation was observed under 
normoxic conditions. All stable CPT1C gain-of-function transfectants except for the clones 
derived from MDA-MB-231 cells displayed significantly reduced doubling times if compared 
to the control stable transfectants. But if injected subcutaneously into nude mice, the MDA-
MB-231 stable transfectants showed a significant increase in tumor growth when compared to 
the vector control. 
Continuous proliferation imposes a number of problems because of an increased metabolic 
demand and microenvironmental changes in response to an increasing cell mass. Thus, signals 
that simulate cell proliferation must also participate in the reorganization of cell metabolism 
to allow quiescent cells to start proliferation. The metabolic adaptation of cancer cells is 
mainly believed to function through adaptations of the glycolytic pathway. Recent studies 
nevertheless show that some fatty acids play a role in enhancing cell proliferation and 
represent an important energy source. Tumor hypoxia induced by rapid tumor cell growth is 
present in all solid tumors and represents an important threat on tumor cell survival. In 
additions, hypoxia in tumors triggers the selection of more aggressive clones that are able to 
adapt to the hostile microenvironment. In mammalian cells, the cellular response is mainly 
mediated by the HIF transcription factor complex which regulates a wide number of target 
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genes involved in angiogenesis, metabolic adaptation and metastasis and thereby orchestrates 
the tumor phenotype. 
Previous studies proposed that CPT1C has a regulatory function rather that playing a direct 
role in the import of LCFAs into the mitochondria. This is supported by the fact that CPT1C 
is highly expressed in the hypothalamic feeding centers where it is believed to be involved in 
the regulation of peripheral energy homeostasis (116, 176, 189). The function of CPT1C in 
cancer cells might thus be similar to its function in normal tissue. If induced by HIF 
stabilization in response to tumor hypoxia, CPT1C might sense energy availability and 
integrate this information by activation of downstream signaling pathways. Activation of 
these pathways might induce changes in cell metabolism, for example by activating CPT1A 
and CPT1B which results in increased β-oxidation rates, which subsequently regulate cell 
proliferation. Reduced CPT1C expression under hypoxic conditions might therefore result a 
decreased activation of the downstream pathways leading to a reduction in cell proliferation. 
Constitutive expression of CPT1C in contrast may lead to the activation of hypoxia-dependent 
signaling cascades in the absence of HIF stabilization which results in the induction of cell 
proliferation. Although the metabolic phenotype could also be explained by a direct function 
of CPT1C in the import of LCFAs into the mitochondria, the localization of CPT1C 
expression to brain regions involved in feeding behavior as well as its low expression level 
favor a regulatory function of CPT1C. 
As a next step, we examined if changes in CPT1C expression also affect cell migration and 
invasion. Tumor metastasis is also regulated by HIF stabilization and is believed to function 
as survival mechanism for tumor cells.  
Stable CPT1C loss-of-function transfectants displayed a reduction of cell migration and 
invasion in in vitro Boyden chamber assay. Surprisingly, the reduction of cell migration and 
invasion potential was observed under normoxic as well as hypoxic conditions. Constitutive 
expression of CPT1C, in contrast, resulted in the induction of cell migration and invasion in 
the Boyden chamber assay.  
However, mice injected with CPT1C stable gain-of-function transfectants co-expressing 
Luciferase, showed a reduced lung-derived signal if compared to the control mice. The 
chemiluminiscent signal correlates with tumor growth in the corresponding organ. Mice 
injected with stable control transfectants showed a dramatic invasion of the lung tissue. No 
further signal was observed in any of the mice over the course of the experiment. 
To examine whether the mice contained any micrometastasis that were too small to evoke a 
luminescent signal above the background, all organs were extracted, sectioned and stained. 
These stainings showed no micrometastasis formation in any of the examined organs except 
the lung. It might nevertheless be possible that the extracted organs contained micrometastasis 
in parts which were not stained and examined by microscopy. (preliminary results) 
The lower amount of lung infiltration observed in the CPT1C-injected mice might result from 
an increased migration potential that allowed CPT1C stable transfectants to leave the lung and 
invade other organs. Our experiments however were not able to elucidate this effect because 
of the rapid lung invasion observed in the control mice that forced us to stop the experiment. 
Further experiments are necessary to elucidate the in vivo migratory phenotype. The induction 
of cell motility represents only one aspect of tumor cell metastasis. Tumor cells that leave the 
primary tumor have to adapt to the blood flow and after invasion of the distant tissue need to 
survive the new microenvironment. These aspects of the metastatic cascade are regulated by 
independent pathways. Our stable transfectants expressing CPT1C might either not be able to 
overcome these restrictions or the experiment was not long enough to result in the formation 
of visible micrometastasis in the mice. It is possible that constitutive CPT1C expression 
results in the induction of pathways that regulate cell motility without affecting pathways that 
regulate other aspects of metastasis.  
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Although HIF has been shown to regulate both cell proliferation and metastasis, the 
underlying pathways are different. Our results show that cell proliferation and invasion are 
influenced by CPT1C expression. What remains unclear are the mechanisms underlying these 
phenotypic changes. The induction of CPT1C in response to HIF stabilization might regulate 
the activity of a number of different pathways leading to proliferation and migration. But it is 
also possible that CPT1C only activates pathways that modulate cell metabolism. The 
observed phenotypes may therefore only be side effects induced by the metabolic adaptation 
to hypoxia and the subsequent increase in ATP production.  
Further studies are needed to elucidate the pathways that are regulated in response to changes 
in CPT1C expression. These studies might elucidate if CPT1C regulates cell proliferation and 
migration via the induction of two different pathways, or if the same signaling cascade 
activates both processes. 
We also examined the effect of CPT1C gain-of-function and loss-of-function on cell 
morphology. A previous study revealed that CPT1C depleted murine ES cells display a severe 
change in mitochondrial morphology and the accumulation of lipid droplets in the cytoplasm 
(236). The mitochondrial phenotype is characterized by swollen mitochondria that display an 
abnormal internal membrane structure and a loss of cristae structure. This phenotype was not 
observed in our T98G CPT1C loss-of-function stable transfectants. The knock-down achieved 
by the introduction of siRNAs however is only partial, while the knock-out achieved by 
genetic approaches for the generation of knock-out mice is complete. The remaining CPT1C 
protein might therefore be sufficient to maintain the mitochondrial integrity.  
In contrast to CPT1C loss-of-function stable transfectants, stable gain-of-function of CPT1C 
in MCF7 cells displayed two distinct morphological changes if compared to the control 
clones. Examination of the CPT1C gain-of-function cells by electron microscopy revealed 
that these cells contain vesicles of unknown origin. CPT1C contains two intermembrane 
domains that tightly associate the protein to the target membrane. CPT1C expressed above 
physiological level needs to be localized to a cellular membrane. These intracellular vesicles 
might function as storage vesicle for the excess of CPT1C protein that due to space 
limitations can not be localized to the mitochondria and/or endoplasmatic reticulum.  
In addition, these cells also display an increase in cytoskeletal stacks. This observation was 
confirmed by Western Blot analysis showing an increase in tubulin expression in the CPT1C 
stable gain-of-function transfectants if compared to the control clones. It is well established 
that the cytoskeleton is the intracellular machinery responsible for changes in cell morphology 
and motility. Migration is driven by a continuous cycle of actin and tubulin polymerization 
and depolymerization (76, 121, 144, 173, 190, 201). The observed increase in tubulin 
expression results from the induction of metastasis and might not be directly induced by the 
constitutive expression of CPT1C. 
Elucidating the mechanism (s) by which CPT1C influences the sensitivity to hypoxia, cell 
proliferation and cell motility may provide a novel approach to improve prognosis of 
treatment-resistant cancers and present a target through which to sensitize hypoxic cells to 
cancer treatment. 
 
Overall, the results presented here give further insight into the function of CPT1C in normal 
and cancer cells. 
Our data show that CPT1C expression is regulated at the step of translational initiation in 
response to cellular energy availability. Furthermore, our results demonstrate that CPT1C 
expression levels influences cell motility and proliferation. 
Although the results presented here add further insight in to the function of CPT1C in normal 
tissue and in carcinogenesis, the studies revealed a number of new and yet unsolved questions 
at the same time. 
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Abstract 
Radiotherapy represents one of the most effective tools in the treatment of human cancers. 
The development of new linear accelerators’ like the TrueBeam allow the increase in average 
dose resulting from the removal of the flattening filter. The use of flattening filter free (FFF) 
beams reduces patient treatment time by increasing dose-per-pulse as well as dose-rate and 
might therefore achieve higher treatment efficacy.  
Ionizing radiation (IR) induces a number of cell signaling pathways that include not only 
DNA damage recognition and repair pathways but also signaling cascades induced by 
unfolded proteins and organelle damage. Although the cellular response to IR is well 
established, the impact of dose-rate and unflattened beams on cancer cell survival has not 
been fully investigated yet. 
The results presented here show that clonogenic survival is reduced upon treatment with 
ionizing radiation using high dose-rates. Furthermore, we show that the use of unflattened 
beams reduces cell survival after irradiation through an increase of dose per pulse in a total 
dose-dependent manner.Understanding the mechanisms by which dose-rate and dose-per-
pulse influence cancer cell survival might propose new approaches for the therapy of 
treatment-resistant tumors. 
 
Introduction 
Recently, the TrueBeam linear accelerator (Varian Medical Systems), which allows photon 
treatments without the flattening filter in place, was released for clinical use. The removal of 
the flattening filter leads to an increase in the average dose-rate, which allows a significantly 
faster delivery of the dose to the patient. The beam pulse characteristic of FFF beams is 
different from the one of classical flattened beams. An FFF beam running at the same average 
dose rate as the flattened beam has an increased dose per pulse (instantaneous dose rate) and a 
lower pulse repetition frequency. This makes it possible to investigate the tumor cell survival 
under an increased instantaneous dose rate. Whilst there is evidence in the literature showing 
that prolonged treatment times lead to an increase in the tumor cell survival (1, 2), very little 
is known about tumor cell survival for increased dose-rates. 
The cellular response to IR, as it is applied by the linear accelerators used for patient 
treatment, involves the activation of multiple signaling pathways (2). It has been well 
established that cells exposed to IR show DNA damage, increase mutation rates, chromosome 
aberrations and finally apoptosis. DNA damage induced by IR arises not only from direct 
effects but is also induced by reactive oxygen species derived from water hydrolysis. Because 
of their impact on genome stability and proliferation, DNA double strand breaks (DSB) are 
the most damaging DNA lesion after radiation (4, 5). Once detected, DSB are repaired by two 
specialized pathways, namely homologous recombination or non-homologous end joining (6).  
Although DNA damage represents the most severe threat to cell survival after IR, other 
cellular structures like proteins, lipids or organelles are also affected (4, 5, 7, 8, 9, 10).  
Additionally cells are also impacted by so-called bystander effects which include reduced 
clonogenic survival, altered gene expression and apoptosis due to signals transmitted via gap-
junctions or factor secreted to the medium by damaged cells. Bystander effects induced by the 
irradiated cells lead to the activation of signaling cascades that affect the response of the 
irradiated cell population (11). 
Glioblastoma multiformae are among the most malignant human cancers. IR represents one of 
the most important therapies in brain cancer treatment because of its independence of the 
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blood-brain-barrier which limits substance application. Glioblastoma usually have a poor 
prognosis because of their intrinsic resistance to radio-and chemotherapy (12, 13, 14, 15). 
Here we report that the induction of cell death in brain cancer cells in response to irradiation 
not only depend on the total dose delivered per treatment but also on dose-rate and dose-per-
pulse. Irradiation of T98G and U87-MG cells with different dose rates revealed that an 
increase in dose-rate leads to a reduction in clonogenic survival. In addition, we were able to 
show that independent of the dose rate, FFF beams are more efficient in inducing cell death 
than the more commonly used flattened beams because of the higher dose that is applied per 
single pulse. 
The results shown here might present an opportunity to investigate the effect of dose-rate and 
dose-per-pulse as a potential therapeutic option in radiotherapy-resistant cancers. 
 
Material and Methods 
 
Cell culture 
The human glioblastoma cell lines T98G, expressing mutated p53, and U87-MG, expressing 
functional p53, were purchased from the American Type Culture Collection (ATCC). The 
cells were maintained in monolayer culture in Dulbecco's Modified Eagle Medium (DMEM) 
containing supplemented with 10% FBS, 1% L-Glutamine and 1% Penicillin/Streptomycin. 
All cells were grown in a humidified atmosphere of 5% CO2 at 37°C. 
 
Irradiation  
Pulsed photon beams of the TrueBeam linear accelerator (Varian Medical Systems) using the 
nominal energy 10 MV, with the flattening filter in place (further X10) and without the 
flattening filter (further X10FFF) were used in this study. Characteristics of the two beams are 
in detail summarized (16, 17, 18, 19). In short, the absence of the flattening filter leads to a 
decrease of a beam’s mean energy and to an increase of dose delivered per pulse (DPP) of 
radiation. Each beam can be produced at different dose rate (DR) which is achieved by 
modifying the pulse repetition frequency (PRF). The change of dose rate does not influence 
the dose per pulse (Fig. 1). Table 1 summarizes the quality index (Q-index), which is an 
indicator for the mean energy, dose per pulse, and pulse repetition frequency for beams and 
dose rates used in our investigation. 
 
Table 1: Beam characteristics 
Energy Q-index DPP DR PRF 
  (MU/puls) (MU/min) (Hz) 
X10FFF 0.691 0.13 2400 360 
   400 60 
X10 0.735 0.028 600 360 
   400 240 
   20 12 
 
Irradiation of samples was performed in the reference geometry, i.e. source-to-surface 
distance of 100 cm, field size 10x10 cm2, at the depth of maximum. The samples were placed 
on 5 cm of water equivalent RW3 plates (PTW). The build-up for every beam was provided 
by RW3 plates of appropriate thickness placed on top of the samples. In the reference 
conditions, 100 MU corresponds to 100 cGy, hence dose per pulse expressed in the units of 
MU/pulse or cGy/pulse is the same. 
Additionally an experiment was designed comparing X10FFF beam with X10 beam for the 
same DPP and the same PRF. The irradiation with the X10 beam, DR 400 MU/min was done 
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as described above. To achieve the same conditions for the X10FFF beam, it had to be 
attenuated by a factor of four. This was achieved by 30.5 cm of RW3 plates. To deliver the 
same dose the number of MUs was increased by a factor of four and to radiate with the same 
PRF a DR of 1600MU/min was used. 
A diameter of a sample plate is 30mm. Three samples for the flattened beams and only one 
sample for the unflattened beams were irradiated at a time in order to deliver homogeneous 
dose to the samples. An analysis of dose profiles of corresponding beams shows that dose 
within a sample should not vary more than ±2%.  
An independent verification of absolute dose for the irradiation setup was performed using 
gafchromic film (EBT2, ISP). 
 
 
 
Figure 1: beam pulse history 
The pulse pattern of a flattened and a non-flattened 
beam for the same dose rate (400MU/min) is 
significantly different. The flattened beam has a high 
pulse repetition frequency and a low dose per pulse 
whereas the FFF beam has 4 times more dose per 
pulse and a lower pulse repetition frequency. 
Increased dose rate (2400 MU/min) for the FFF 
beam is achieved by increasing the pulse repetition 
frequency. 
 
 
 
 
Clonogenic assay 
Exponentially growing cells were plated into 30mm Petri dishes. Cells were exposed to 5Gy 
or 10Gy of irradiation. Following irradiation, cells were incubated for 10-14 days at 37°C in a 
humidified atmosphere of 5% CO2 for colony formation. Colonies were fixed with methanol, 
stained with 1% crystal violet and counted. Colony plating efficiency was calculated as 
previously described (20). 
 
Statistical analysis 
All data are presented as means  standard deviation (SD). The data was analyzed using the 
statistical program SPSS version 16.0 (SPSS Inc., Chicago, IL). Differences among the 
groups were compared by one-way analysis in combination with post hoc Scheffe test. Two-
tailed values of p0.05 were considered significant. 
 
Results 
 
Cancer cell survival after irradiation is reduced in a dose rate-dependent manner 
To examine the effects of increasing dose-rates on the survival of established brain tumor cell 
lines, the glioblastoma-derived cell lines T98G and U87-MG were irradiated with either 20, 
600 or 2400 MU/min and a dose of 5Gy and 10Gy. Cells irradiated with a dose of 5Gy 
showed a reduction of clonogenic survival in a dose-rate-dependent fashion. The reduction of 
cell survival was only significant in cells irradiated with 2400MU/min if compared to cells 
irradiated with 600MU/min (Fig. 2A). In contrast to the irradiation with 5Gy, clonogenic 
survival was markedly reduced upon irradiation with a total dose of 10Gy and increasing 
dose-rates (Fig. 2B) in both cell lines. A 30-fold increase in dose-rate from 20 MU/min to 600 
Appendix 
91 
MU/min led to a 2-fold decrease in cell survival in T98G cells irradiated with 10Gy. Further 
4-fold increase of dose-rate to 2400 MU/min reduced cell survival by further 1.7 fold. 
Clonogenic survival of U87-MG was reduced by 0.6 fold and 0.8 fold respectively after 
irradiation with 10Gy.  
We have hypothesized that increasing dose-rates should lead to decreased cell survival in a 
close-to linear fashion. In contrast to our hypothesis, we observed that clonogenic survival 
was, although reduced in cells irradiated with a dose-rate of 600 MU/min if compared to the 
20 MU/min, much higher in cells irradiated with 2400 MU/min if compared to 600 MU/min.  
This effect could arise from an overload of the DNA damage repair machinery by the higher 
number of pulses-per-minute (Fig. 1), we further investigated if the reduction of cell survival 
could be a side effect from the beams used in the experiment.  
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Figure 2: IR efficacy is increased with increasing dose rates. 
T98G (empty bars) and U87-MG (filled bars) cells were irradiated with (A) 5Gy (B) 10Gy 
with dose rates of 20, 600 and 2400MU/min. Clonogenic survival was accessed as a measure 
for irradiation efficiency. * p 0.05; ** p 0.001 
 
The use of flattening-filter-free beams increases IR efficacy 
Due to the limitations of the TrueBeam linear accelerator, the irradiation using dose-rates of 
20 and 600 MU/min were done using the flattened X10 beam while the dose-rate of 2400 
MU/min was done using the unflattened X10FF beam. The only dose-rate both beams have 
available is 400 MU/min. Although both beams deliver the same mean-dose as well as total 
dose, the dose that is delivered per pulse as well as the number of pulses-per-minute differ 
significantly (Fig.1). This prompted us to investigate if the reduction of cell survival was also 
influenced by the beam used for delivery. 
T98G and U87-MG cells were irradiated with either the X10 or the X10FFF beam with a dose 
rate of 400 MU/min. Clonogenic survival assays revealed reduced survival rates after 
irradiation with the X10FFF beam if compared to the cells irradiated with the X10 beam (Fig. 
3A, B). Clonogenic survival of T98G cells in response to irradiation with the X10FFF beam 
was reduced after an irradiation with 5 Gy (Fig. 3A) but not significantly while it was reduced 
significantly by 2.4 fold with a dose of 10 Gy (Fig. 3B) if compared to cells irradiated with 
the X10 beam. The reduction in cell survival after irradiation with 10Gy although still 
significant was lower in U87-MG.  
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Figure 3: Flattening filter-induced reduction in cell death after irradiation. 
T98G (empty bars) and U87-MG (filled bars) cells were irradiated with (A) 5Gy (B) 10Gy 
with a dose rates of 400Mu/min with either the X10 or the X10FFF beam. (C) Dose response 
curve of U87-MG cells irradiated with either the X10 (full circles) or X10FFF (empty circles) 
beam. Clonogenic survival was accessed as a measure for irradiation efficiency. * p 0,05; ** 
p 0,001 
 
In order to test if the observed decrease in clonogenic survival after X10FFF irradiation could 
be observed over a wider range of doses and if the effect increased with increasing doses, we 
irradiated U87-MG cells with both the X10 and the X10FFF beam in a dose-response curve 
with 400 MU/min (Fig. 3C). As suggested by the previous experiments, irradiation with the 
X10FFF beam reduces clonogenic survival if compared to irradiations using the X10 beam 
throughout the whole dose-response curve. The survival rates while significantly different 
after irradiation with higher doses were not significantly different after irradiation doses that 
are also used for patient treatment. 
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Increased dose per pulse reduces clonogenic survival  
Although both the X10 and the X10FFF beams deliver the dose with a dose rate of 400 
MU/min, the dose delivered per pulse as well as the pulses delivered per minute differ 
between the two beams (Tab. 1). The results obtained might differ between the beams because 
of the higher dose-per-pulse delivered with the X10FFF. To test that hypothesis, we irradiated 
T98G (Fig. 4A) and U87-MG (Fig. 4B) cells with 5 Gy and 10 Gy using the X10 and the 
X10FFF beams in a setup where we reduced the dose per pulse of the X10FFF beam to the 
level of the X10 beam and the dose was delivered with the same number of pulses per minute.  
Clonogenic survival assays revealed that clonogenic survival indeed depended on the dose 
delivered per single pulse. Cells irradiated with the X10FFF beam in the dose-reduction setup 
showed the same clonogenic survival as cells irradiated with the X10 beam.  
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Figure 4: Flattening filter-induced reduction in cell death depends on the dose per pulse. 
T98G(A) and U87-MG (B) cells were irradiated with 5Gy and 10Gy with either the 
X10(empty bars) or the X10FFF beam (filled bars), with reduced dose per pulse. Clonogenic 
survival was accessed as a measure for irradiation efficiency. 
 
Discussion 
The new TrueBeam linear accelerator offers the possibility to irradiate with a higher dose 
rates than commonly used in radiotherapy. This is achieved by the removal of the flattening 
filter leading to increased average dose rate and reduced treatment time in patient treatment. 
Although it has been speculated earlier that cancer cell survival can be reduced with 
increasing dose-rates (1, 2), few studies have previously aimed to elucidate this hypothesis. 
The results presented here show that clonogenic survival is indeed reduced if the total dose is 
delivered with higher mean-dose rates in a total dose-dependent manner. Due to the 
limitations of the TrueBeam linear accelerator, the higher dose rates can only be achieved by 
the use of the unflattened X10FFF beam. This raised the question if and to what extent the 
change of the beam is responsible for the reduction in clonogenic survival. Indeed, cells 
irradiated using either the X10 or X10FFF beam show a difference in clonogenic survival 
which can be explained by the higher dose-per-pulse delivered by the X10FFF.  
Further studies are necessary to elucidate the mechanisms by which higher doses delivered 
per single pulse increase cancer cell death and how normal cell survival is impacted. The 
delivery of higher doses per pulse might reduce cell survival by an increase in DNA damage 
induction. Radiation-induced DSBs are the most harmful lesions that arise after irradiation 
because of its impact on genome stability and cell survival (6). Nevertheless, lesion affecting 
protein, fatty acids or organelles may play an important role in the induction of cell death 
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after irradiation. The reduction of cell survival observed whilst reasonably explained with a 
higher incidence rate of DNA lesion might nevertheless be derived from DNA damage 
independent pathways. Investigating the role of the unfolded protein response in the 
endoplasmic reticulum or cytoplasm might therefore give further insight into the pathways 
induced by changes in dose-rate and dose-per-pulse. 
A further increase of the dose delivered per single pulse and the combination of high dose-
rates and high doses-per-pulse can possibly reduce cell survival also in the doses used for 
patient treatment. Additional studies will show how the use of unflattened beam will affect 
cancer cell survival if the dose is delivered in a fragmentation scheme and if this effect can 
also be observed in in vivo experiments. 
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